var title_f19_36_20032="Management of single magnet ingestion";
var content_f19_36_20032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of single magnet ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 408px; background-image: url(data:image/gif;base64,R0lGODlhSgKYAcQAAP///wAAAIiIiERERLu7uyIiIt3d3REREZmZmWZmZjMzM8zMzO7u7lVVVXd3d6qqqj8/P9/f38/Pz5+fnw8PD+/v739/f19fX7+/v87OzgAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABKApgBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjTcBkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmgjnABrK+wWq6xa7O0t7hMtrllu7y/wD6+wV/DxMfIMMbJWcvMz9AiztFT0zoHB9TafdbbTr4HkQInDAHZDQEPAA8BDSjYS+EMKOjq5dne+Tnd+krDCgEWsKjHAp4SefTS9VuIgx9DI/8CrgugAKCCedgERFKwoB0AdJAGGABgUAQ7BeEG/0ysqACARkjjFgCEtGDBgJAG7t08sABkAAcdxb2kSDKbTJwAAIIc9/Chw6ZDIgpkp/LmOHgEO7obge4qPpMeEwQQwA6SAo0OABQIYAAgghEFDjBAECDBPZceEY7oeE5hUbVyCRAFSEDwV6j6niIGInWiOwdj/2b1KGAtpLQlHeN1wG6rT0gP6JoNuvFuZ5IB5hn4zIBg0Y4ty6UGuODu4sS3mzQ+DdnrxwBvtfLd/HfEaaun8SY44TbuSBGm87L9fTU1urd/4zIQ3JK27dzbFIPfAU4c78jwFoTj6BEkQMyH2YWrq1nE0IDz6duM1CC6u5dArSePekSlN5NISQX03f940YjHYENKJPfghN9QCFGEHlmoYRIObhhDhx6G6AWIIrJAYokoWnFiiiesSMIATO1DAIs0ruBijdLQIMB8/QEAIwkCqHRCkDbOOAKRJfyIo4c34tghO2+15Y6S9gk5QwBGqkDlkhY2WaMvC6wV4wkNpCVCRwwMMFMCBkSSgGj0EakmJMuRQBEkbxEJGUyRIEBAOAe8BeMABSQg5ABmcpmPlzT64tM8KBQQY5sGDOBORwsgOQJdDMipkmDPSTNOZS6p5JePTB0wDgJyqTkSpZQqipusNDgaCaRkJoqmksAhicBMbMk5TqwjYAkAAgWU6tJadv1ILFtUwuhAnbSGV+3/lSWEGVkKdEWpwJTjsGOAAC2plZa4wgJArDQzIqvsCIEiKoKqLrUaIwFxCXStNoyyCOKOkPR4E0wAEJjAS2uNW9Ww0xXbbrJBMjDfRaL5CaigYypg5b4NcqxMHRJn6fEz/aZY8hUOlDsyNCeX2PLKMLcYs40z1xzEyyHivIcBYo6wZQqaOhF0EsmCp/OGXrpbr8g6CJaDkj/f4MDGqAJJdZVRDC2EsUlVlgC1iB2tYdIQ86RF1Do0MGbVLGi9hNuMZSnW2lCJ3eUOyLKqb2VrXeRjSAw4sJV9Ld0JHAlO803RPEN9ahkCaUISaJ8/vsQRAIa/xSrBI/xpDgJwhjpn/5yOR7Js37jaF9fifwcwQOCDu9QSwgsIJhgCtOMVEuIBrHUASGnBuVxbkRR2p9m0iwVJWzt+nZvdFHaoPNiiJVpZToFWxgADZz2QjaEfjRMZqZ27cr3ECHSkDpGBrnOAYLhCLQCmAIA/frLymkAvq2muPcCnwVLJAdKSuAJgD3SQgFgBticp7XGPLN9TidrUIxDBCSYmZhNcR2YUNNupRSV0IQGnGlAuLHlwAAmgIAAEhzmRFe15NkNB0g7gPewgqQAIcJ5L7JIOROmthcd6IQASJyQcKi1IbZKEASBDL/kpDV9AdBcBADIAfamrYdDyH8MUFisiigCHJUASCnUoAP8ePsCHPIFT75x2LEngsGgdnMWPnParSPAMOyacxdfUmCyuTQh6f8RbstT3Lhw6UFIfCZR68GEspYnAi2pJn0QaIEDskKAjlTITjOhHySgKsQFgo9eO+pekLbJvVOYroiWxZoDsLZABiGyAItNjtkfOQoVnmuTG2DhHVxTgXGxpwKXyKIKv4VIa6oheDGWmgyf2SpWte1295qGAOjVSiJAEo/IKULo1uqmNwKncaDzZugJYcYgXY5vPTAnCBKbyi6vUXYYGJs1RJqVOQ0kAG+W5HOVpjHci6KXuEqattRivmMvJZ/2WF8hllgCQRQBlGMinArhdAZOKgiiDNAqEgSn/IFRbeMn72nY1KwiGc1ziqNEcytJHtLRYL43ph2Sq0hegTQYWNcM+0QC3m4axpErQFILEUNPbeElTYMQB2vzYgpyywKdHKqlTbYk1FuyUB0z1ASR7Oia3TbUIeiJhyo7wVRPRdAdIjScNoPqCsqKArRUFagmuatWWZRUISOJqU+WKBF+5rq98fUFRF3NUK+GQO+YQCL7wJBh1VBNzM8GYWhIokDwCBHmUlSfVfDIOy5gzcp+jXJAMOJO0yGlNSawL8eizubF49rR0uqJZtrML0B6gTTOCX+/oZJYh3smcygvWOHdbl94eJUMiOAsJygQqNynObz5bk7IWC4nTsQ5I/6u7yGrTwsIjzY6ytutVZhu3QhImQGUBtQyhzDESzwqEvJlTF2rdtCeJzDSm0ottVOHiJ2OhkCRv8Z77Oom5UWVjS79s4QlTmMEGbPBd9rmtOs0Fv3UG9KMfudT7POVbhYlAoq20SaLYyGFQjaBND9hphRFav+VEJgEGxK1gBCJMINLPfuOAsQFwS64TsPC/PNmqAdH3IgB6eIC+XdYBRaNABgqgxuohgIDBN8EGX7BgDX6wUEEa0HbOCJFwAYpCiHS/jwyPJ0g6lQwGGza0WomGbPxaahkqFkgZC1QwYkBwXXzQFvPxiBvTYZ73vEJzjEN+8Awo7hZ2RQ9Ptk9TdP9d7WaRLkrth7G+YOI4/hQrY6W5z6S65iP7yEEhYWk1FFllDckl4K1C08KUQuJ0shlPMcIYOwOAXA8doDc+svHPcAysQFGlZzcBmpyWwVNemZU6F7C5bjtgR7vYEufltM843DT1jByAPwFw6p4K1iODrcjJjR3S26kBdy4zGVCmQBlLlQ5WuSRqAlBWON4GOC8AytHfE2BUTVvxtLbZ+FiFlBuInz6SEIsyrt8luceFXKWzAkgSVEb8p+oK1LtnJMv00dKKbDzmwbW0aTmim5op1CU56U24Elz7Y/jlwZ7aV+0henbGsHRxAmcEo9UWKtwsVqg/N8a9BArA5/r8ZsX/lLRdZU3cAAZbLbQoW3RJMZpSnltLv8unX2mz6115NMtIlDeu4ZaaXUOJZyf5nWSD3VDi7ATnWi4OJP7I9zIRRrl93LRPoZtF2CVvN9IX2jtTPezuyzPYxJrdgmc3xfEOQwIs1cqGqdIVDBQFWmC3wPIiQJ4hnwei53cXh1YmUwWX54JImTakzV/Bo1yOylllSnuzxrz2uJfh7JOQ+hWknqmVO0zuWRH6fniJrXfu0FV/BPxxqI08rA+CW4ffg+LPCiK5Vf4ymk8Sxnth+tQnz+6VKr7IkiC4dLmsYh9XApC873gCYT7HxTGC+p4zd5lrk2JTk8fbWS7+0lUZZjET/+pAXYIyX/oVfhdye08jPqOycMnHc9YWYIdxPbYkgVUDbwakTmp2Jg1WYMviI8shUXkUExIBPv/TYdfTJjlWSe7jI0YGfgoIIQxIfuRkJ9mHUHPWMC1WPiwmf4IWIwJoF5viRuTEadNBTEE0alUTa9pWKjtYKXE3g0dgfYuyA/K3hHZSgOIGYEOygUnWg/J3bvpjScd0gwXATewScir3dAnHPnDXaBBHhZ43fjeQhY5UTHjShdS1cAPzfj8oPgRQdAcAZhIzW3UXW6LWRkaihLpzOW74hETSh03IFgZDh0Rghd6giZh4hTXYiS3FifwCinboUKJIih3ziTYAV54Xff+9d4d081Sx2IAwcFLRV4rL9C88Mg9bAjcyKFiuKB6syIql9IprNYtHElvKdQi/2ATGCHMv9SSHIyUT1oyPEIwdhYwpQIwyAFdIMlLM6HpT8IyCZYfaoo1lshepMTpsYmzfBFv0QQLuBVl4UgLzGF/U5QpNJ4AUQYAZaH7oV40wAhzf9Bsw4TRNZ5CRARyFco/mx46aR3hC9H/0eDgGmCSAgznIQi2C4TvAg3imNZCodl3pFRK+017jFQlVIV2r1Y500lpjEpCDQloJ6FsAYU4aWSgXaX8taV0X4VmIk04QmQKnmIpccSspAGaNZikFExBDwyklxoPymBZldgIJNj7/2UAvTgNlGxZjL8ZoVVlMLdGLBSAyULmBMLKVGkYAOzISzBc75gKCOwKDHYYCCaeOAoFjIdg+AqZw26NcyHWBH9RGGYZlbFmWskNNY5KCdPFlY/JLhBSVq3FmmXIoiXIC+uYqZpZxIDdJ7pAhfJkNpwJiaDZkgUJX+9MqRkaUdvgoKZCOuURKGukrwOJhTzcCxaaIh4ebhJZ8XeRLuLZoX5cuogYwvSOQIlBHyxOETpNUuRaEQJSb9OGbt9l6X7cpRQNF1xSFI0BGfDZXJpdkzimchFeTwzZoxhZslcgzkkCekVZFQDIf3fZF7emDIWgsUTiEsNSeb3dVzyKFjcaa/594jirQLfIFLhMxLuWSYOhydTz4bQW3m8mZbhG6QskiSq6wcW8Ilg+DYhaKnHGJLq8kKWrZlIfpZFFEod/JbeuJWxgnerlEY4a3hC+HXSiaVbwUeBoqJOTifed5cvd0cE/XeXP4YdTioSyqJJ1nnxXqhWVIpKq0YvBiYKS0LiZQlCyjI7vYOpHhdu5km1t0YjPxc4soAoMXCYgpGgABkmB3dniIPwk0n/s1UGxBiCSqj6W1b2MqiIhHpjvXokz1Et+ZiJcjapT4IhmJo+GJkHmqKT4Rhzk6eNvkoDtWmwYzMDjpM3HKNlIXKidFESPBNX14iIvTqW9XdUH5OespoP/RuCGTVySwsKRIQI5QgKUk0yWkpwJ3hQiw54xFaavMAKyoeAzCigzFOqzAcKzE0C8nZY27OgPsiYw39aw/QKuNd4syYK0khVPiyK029Vd2CVTcWA24aAPK5TZwdVfaKgJTswLTiq3QF4Yy8iKzCFWXJ4P4OqM8UFbe431zagLjCgPWSDOqeAMjha7aeJ0AFQPPR3IyBK86kHzxamEzcK/d+q9tdbECK45OpVc/MLC6Wq4rIDznZ3QqgX5wYkmIhZOnVhqe1ZOEugCh05194iMsCSw8BzgdaQ4f2ZPP5X3oB382V4/xFbMViUB4IpPlV48+KDypxSYBOJAkG0e3M4//8JWzrsM4KokqhCKTAZiGJIlOn5NaljS12TUPnPWIlWUZ/vRhs4VYtSRbqpWnNNiqNfBtkRc0mbk2M1aYfoRibESa5HaCjIaZYzlMPaFtDnQWHqSGISS451OjOOhbGBiacilEN2YqBjZh9TOWDhiC9jmhnSIkkIuYRTi6vLM2kClwLbS48zNmKwlSmYm4kbtKqYm6J3CWTmaBm0S4IKhjPOY3jOtfYIMkXAmxjSeyBVqbk0skximn9hlqBHBpwMFGyXY4yZmd0BthCcQ2DIlHBOCdOSqe/PlqV5qDLRaFZaqF2pl9AFov3fumAKWcFPdoyiYk9OtoVLVve3ZsWOKd/8emJM/rveSZVAGKOfqbnLVpa0H4RKTWpsFVFzU3p+NZt6E4AwwqlQKHpPhzmWEYofrGbxUmq00poxPGwVUjLho6ogIwvltZvNBEYMXChSxWo+t7cMaSpGmBwvLrgxmsoEZqNV8ETAn8ayqKwycKS69rwhOnDkkaLvVrwBU3TUPzw0TSSrjDwkjcpj1qnzrUcoX5YC5VsG3zpc1bFZtaMVwHqgoWDlpXdZ1qtD+DqXBKMNpCGNFEW+2WZKYKTeBIswTJYpS4vmqLOX+6dJvaw1SFMJYYDlBrR3n1pXFkpmPaT38HRPQ0D5PKNnTMpaNivmLbPkPDyGUXMHpqDohEkf+sC0SPOsEeOLd4Z8EsxWbrWgZnFA0kTK/Ep7xGUMvh16sO6wjKGgzDnAd0ATbIWgPF/AvLfAdqIhfJPMZ2GwM5ZYwBy7kxcM1D8ACZ+iKJQimSG833Nc0bi3rWcM1Z6AJilLBgZVinRwIhw64qMVbiXCu8HK7m7K7sDLD7/KLa3AO0mQLTsm/t46L1vGb3/IWoY5AXUUDrkTriRBHvFQkLoLQtFFwQk1lm6iZD6R4QrV4nmVp+A1/m15JPmwBmYlsmkQ2s4jPIfNDJS8YrULtdPLzLgqLrlLlifH6eK3p3pELdVVUpCCo1vZhephaTkg6RqbkhCLmHgh1SekVcKjn//grTuifTcQVPEZx07/Jf6+TAeTjAWagemmOEc/p0W63LOUq9oKOeona95Jlr9WdoG23VsmyKM/B2XbzIKoHF9FpuYszDghhlHnhO3rXHsQZdpRSGMBLCwLHF7kKk5YLS2TIdfWnXypzQJvB2CtlvQwGXEX05Q3FpaZiBBDAw1aVQe+HIt/moam1yWXc4myxqnWowv2JL+jXQmJ3ZWI0DIAsGuawCBfDOuPnHu43QvX0Dv80FwAwD3GzYPuLBxw2NFzzd+9LMuYDd1k0I2n0L3a3MyCsFtPrP1PfdsdAhcKKUDxXeRMneJ0Cr1FoFkIQ25H0DdFXf++vLsGDe+z0D/0dEL+fbBfFNBZC0jf2sVS2j395tjj3DLS/UYwYYXKXMshu5Xq5zkuGmfgN1TjBZQAudtsbi0ScmEfCDfxtpf+ATSccVO/xYEaCB1I3WXHTCfA+JSr1zf5bh4goRkPnok2g7W0BpYfiYbIi3HDB5c3iKdz/LC/z9CrYCCVXtSE5jucYC1J+5FYxpLIjUfyJo5d7sgzQtYWMovIs5guNWXpgTcKeX4oaEXgq3Y18J41j3Thm4uZv0gW/OgvUTaC2BZAV0QEV9359LKn6eoZSZP2FYolFWu0zemkiJAo5ELuo7bWgqej8KdH5m1o9ERZMWcdD5v5IANkhoAHwkevrJ5v8IgGoKsEobKufURudZiGfoVulzyrrP+5ueHuqC7km4Dtfv2eniGZycnd0Mvi2QDkftY8PqcIZcc+lKaExxSyZcrdcs3LqKbY9qyOxM40roZEmZ1+r/pREGkDjlkoVPfIa1XmoojKERt9e+1Wzyy+4kbG/ppujwBsq00OS7LAPpDdVASXYK1eyBZ9o1p9oBBV50jkNF1zt86toixDUBPyOkql19kz01m+7TZRavjmV1wXx/GtHxWFWs28lMlvBv8aioKuSHV/KIN3U3XnWMquT4ft6a7QavqgYD7tsLt687T1g1Xwu5mgY5ryOS495tVfQPou/CvN3XovSN4PRMnwf/UL8IUx/1dlD1iYD1Vj8HWn8IXb/1rUBTqjD2ZF/2Zn/2aJ/2ar/2bG/2YN8obx/3tyr3dL+sdX/3zIz3er/ge9/3++73gK8IXx/4hF+OhX/4gzD4iJ/1bd/4jv/4kB/5kb/4T6D4dGj5VIj5M6j5Csj54ef55U35FSL6ukD6pW/6/oD6qa/6RBABEpAjACABEcD6QOD6sC/7tP8DFRAAEDABATABEBAAFZD7PrD7vf/7wT/8xN8DFzAJF7D8PtD8kvD80M8DEjAJr1/9O3D9kpD92q8DwQ8JEPD9PBD+vE/+O+D7kDAB6K8D6v/77a8DFBAAFBD/8k//9p8DFhAA/xYAAoA4kqV5oqm6sq37wrE807V9u1Zg4b3/A4PCIbFYigQixiWz6XxCh0hltGq9YrNBjLbr/YK13DC5bD6j0+o1u+1+w+PyOb1uv+OhgT2/7/8DBgoOEhYaCuYl/hwyNjo+QkYWKlL6BFTSXGJuwmhyZnl+iq6EjqqUmqaipjatspq6vorEylbS1gbd4lLqqu6O9v7eBAvbEYseF8MlK3c2fzJvRj+rTbc0BCy8LAQ0JFpTV7MaBBSggIeXHXMHCIgUBDigYC9wK4goZJ9we3dhPwxLZ4uVgHwETqATCGbdHnMC9sg7Qc8eC35e/gVU+E3IgQNmCiBokAChxjsMD/+0K4BSXr56ATzSQ7nnAb0HARSgHADA4oIBewYYIJEPWzufChiw2+POgM+OARg4CDAApTcGRAs8eLjnqE+lzkriQZWgoQOo7V509PIw4oMDDGwyMJEQLCgY9rAdWAugJTeY2SgCqNkNwFgBFlUyQBBg5AiDBMoRDoBgRN/AZ1GadYdywT9y5jBGZRxjLl0tpaIuHaAtRtouegEMYFzAXQnSpaswVMAtgV6+Ly27vAfcpre1/JJuFfr3JgDUBojuYbAZAGbUe7PJ5GM1AMAF8F6udmH7tpVS2AaUFfFQAIOXTbVpXUnd4/ZyAEdEnboYr7bs/Yii9IBNCuRzFABatYP/XAb6HGhObeTFkdsIvXFX2USQDTeYT4YNplJQJvh2D2rYaPaUTwBVd1ZL2Ew2AoskhPYVhBGW4B0fChiwXnsePdQANw7FM59lD3gG42UBGKCYaADAQ0CPQ9qk04Z6wZNjkAjycRAJ483IhITqBWmTVL/RYxl3gsk0Ek9dDdbYciImiBJOTy1QYIrutFTfbwvICR1QMnbpxipQTdnOjgAQ96ReaWUXHX5HvjVYVHzQdNY/xDXXDnQzvcYCl4EW8akLmDbxmINPiApqqCU0QNtYCOj4G3GP3bOoXy2WYB1miUo1pF4nYoraQ0sOK56qa6TKAqlFiHlTeE4ke2wuJQgA/6A7sXoU7FZBpqWnR4+WGGkDDORzQD4PMNDUudpe28cC5DpKirRpRFtMvfP2QJpPuA7BQJVD3ItvJgKfQzAa6OQDERHt7XEAv0AEbDCg+CwZxQC0RajlLBKbETGyHC9UAgLC5aKxChdf8ZgNAZjsMcjGNuPyyymUglUWKFuhcg0sbzlzyDH7bBoJ5MQFAAEoOXzgxUiOMNYe/Na5hzcs0wregXxI2W45zwrwHYEzRfa00d9d0jU8BhJ11Henhi0ZbAmPZEDCPI8gc9AFA333FaEQcGpeACDgVtcmk5AAyQceTjXPsXEDkABZ86mNA/2oV4AB5LiTgE5N33OAPCp3bf+AdLAaqIAAOp9gOGw6Pfbc5nRvrHddecseBd8OkvMhko+bIIBMbD9302SKi5BAAgg4yPvFivHBNu8A8My77w3lbnTZm4Pk9B4JoD7h77AthSRIs7RcOxaSoJ+++oOYb/vQT4nwt+8MPD8COQA5wPaE5hBPWALcaKMBkDvAsyb0uoM87n7NMYf8rvcO0hXNehEEgALzBz4KIqkB3uBG+dqHC7t5UGgksJnRkDaZ+o2gKwVwHh+GRwCdGS9sBcja1bZHgudFT0oNMQfz4KG0B5pJMvBimwrNgbLc2cggPQuhLEDIxL2J7HBPEAkRulaeJ77CiVh0XwkUUDEjdAVHQYj/D+GgtUVfnBEaPtNiGlHVRk6wERlvVOMcB/IE5WHsZL0yAuxIUcajfWiJdbTjIDcyxs31joZ9LEFbJtgCnL1gkTQr4w8fVEheXNKQQEDhDWm4Ak4SQZLnoGR7Ahm7TOYhjqi0hMj4ULFybC85ZtKNK5m3mB+ijGcAsl8LtaIb6CGPe9+ZDMoQJCW41SZhkznaSyYjtyxpTgTowUceocex9WEzm9rcJje7yT6DuUIxEzxLAixHDieVTgCcFCceoeckyyVyJ/qIZpuS1hbwNQ6XrGNa3a7lkb8FzioHzF31CFNNVWJylV5AqCZFMDI+mDKH5NPeYp730D3kSJEEiGE8/5Engr65E4N9YIoAPIrL8EX0IK3jp/hatDgBOEA0vLEkOBW6UInVTB42SWklWVaQCBbkHTrdnUZDF08ABkYndEtaCjkUQBoWlHwLpI4/rbJBnvWNgI056DVt2gWGppJaDeGnVHF4EOgggE8VHWtGL7i4hnUSTM4K6dgackGnzfCCUYVeQ1Rqwp2cjW4KQGQpaUowsKISsSYRBRWDIB2NgVKxi/Xq7A67iTCa0gcOIBkg5dJVyp4Pp2sUWAQkEDsJUAG0SyjtaVN7LMk29FgVCAAEJhCACUAgABVQLRNmW9vb5na384JtWAV2AT9cgLdNOG4fkosv4oaFYBLwg2mVu/+E6fahusMdLcFyuwcIWLcJ3qXtYb1p3vN202C23cMEwsuE9d7WvSuT7w0oEAAK0HcJ9sVvfmcAXb3pgAf9JUKAByyD/95tCgaWQhIWPDEHs2AMEAaChCcsLwtjOMNkQLCGO2xd1loTAKhVBXpLbOITo/gQNEsxi1vsYmzKwre2xa1u0ejhSNLsxjmWBXP54FxY6BjHeAuyYVOBXT5oFxhEbkEsOHw3JwthvOBlBZTb1+QlFzkV8G0vlbF8YZJ4+ZSy2G8TcbAsGrSkDIfyQpr5uOMoYOQEZwaDdWLLigJnsQRNgs1ZlIQpzCCqTSKYswkA02YZdAoIa+7CoUP55vj/8YGpQoizCDBCaBcARgh1Lm4tFJznwh1JJ68iAaAvvQJDMwjRQRLCorXQaIA9mjp0+s0QKD2kQFMuBpkOwqaju4sK2/iji3lMR/yFJH5AxwEDKhBSBjMUr4wgOw949lnqQ0IRRG0PyEmMTLyxbKloRWv2AZzXdvQeEqSrIfjrhuduyAd3ZPsvCftTgcBGbXf4KSjxicehnhQ4uArSs6SedT8QdDrIPMYbkzrLtw3ktABN6EYNj4vBc8WHBkg73eO+t1Ga/W4A6OkB+aGKr2+MigPMph0q14lFSt2rDVnEMbTGNnOu80IycadIbsKVXiiylijxGQE6B5NqblK0fgt6/0j+csvCI3I1eVQpH7hCDK2uswADpEXm36p0giCzFqSP6yWZFXORs9NAqCPpXGNxUpCA9fJ2PMnWln67OoP0r0HXXJ7C+cfS4XVzc4ya5n7BmK5STYcqCwwVTbHcS87ScvixK+bZaDWq3/WbRsHPoTei35XCdBNM8V1WbDLdqkEuq6QD+ly9DuJMbEnLezAMXv15Sp5+0zU+OEBR/Lb9YLSX6xCDOdrwY9GmuNMjc906KsqWVDusI3fu4DpT1fLDfUDOJg4JJ/XcCZH0g6cdQIvAOq+WAzpebP7z/2FgYr3ldw7y+KBE3tmTn7k8HVT7W6lA6sXyeTxAz51DoQQB2P+DPRzd6eUa3yHG6hULiEgG1TFHS5iK1e1IZaxF1X3dS3Ae5UgHWQGfwAlfXOzLAo7AMD0dnwkI89WdPJwICbwIu4ignG0NhiCgW3DfiEAKiYCL1U3WzjDRNKACOUQPrVmEViyfwnWdN9wfq8xEEnrLwNkQvDzFv92S/6EL790EcyDPVhzKmWmcAqxbNdWQtmWHmsxbUJTL1kggzl2hPExKPrDhT3RDUvxNwJVdH9AGlkgOhmTKS7gDu/CZuUAfZciJH+JhxG0FQBAFuoQRQNRgnNwEZoSc+BneHJRfD6rfJY3fC+zLgcXaC6yedVViCPkgKmXiCsyN0z1Y3dBAseX/Vyh60CiG2ZB5oJe5opVdYixmmSrGYi32gE8gkhBAUg0EowtoRb7cYjOAUgx0TxAsoxBc2UJREgwMIxBMY8kdowo8Rl/JmVu4QDOyQDWqQDtdEAy0RzRyon/RwPR0gyMJm3r84guYzqklzGzggDh6ys21IxGAzjtKExgmoyzmYgsgSAOM3YHho0B6Ejj2ojtIkjeKUhjwIjYyzWadwD+egDeugEJmJG1o5D7YBizGgE04kwL8Xj7OQDaC4dAcAGNUSz16UjdqAkb2gEyOIw8CpAvkjzYwhTlG0kFqIkempA8oJE3SS0a0QOsEhjc802IAoWRoRQFoQwOKxtrwmVRM/5D2EJO4sc5fXcwAzMYA2BICDAAy3d5NJEz1Mcn2MFPSPM5DFGTwjUYJwAs/sqDTcQP9qITRrQ3vrOUJrZDRmQAkDcA7BlUJdMUAMEDVEJDGeQQ95s7jhCV+5FpQsczaKOaz2NIrKVNduU3f8MEPYWVYduVXcmZQdmCRMQ9PHgBallAzvY0NSWFJaUIMVaZdiUB7PMtqQmYLjaUNjVBDcE1eoo0WBhFDEkBTqk1DtCWS6BLAQaRRskA2SkVQUBHWLQDvRE5zTM3v6UzXMAC5pKTqXEw+8Q5AucVY6ltC7lOOmBM5/aLOmCde8uQsTgyCsOYIYcxjFsB3zkZ36kR8hv/O6AQmxgwmtVSMd4LnYxxEbDxGBDkmUdXkoHlENLWKO+mMgsLGFwFO5s2CP1HHZNzT3+xj4dwDzqDnD83hKcSaTEhRbWRWfBZo60yT5hXPSPSPUAiAAYAEn5yUNK3nCRQAKiLobPzUXqgTPOWSxtxPdxaAlvgUPHUMdK5A6wROUJCNU+qELUHGIsEQSxLL9yxP8gAFS5GUO47jEUFoSKGQyhRUmgrZORpiIEqEXT7F8zCoJiQQmT7P+BimaTZICXCUAHDPbI5EVPzNg7bVMLbHA6BH4ETlQXYpCVwUB2IVc44U04yoOhoRULrjXt2kLgpf3p2ApGGQ7pRp7hBAPqj/hmLUqIWiwuQkwAPMRnEkJEqNAANoD7FsTmxQlPEwRpL2RAv5Z91slIZ+QUSmAFJullXo6k5oFbGWQIM2CH/mJ/RZ0HjqgwBR1YGc5x1KSUSgaVup6XtqgvwIDl2qKDqim6qqgGKMJK1SkMNIa3lW1Z4+TE0WqEoWXKvsp78cXKvSHFOMhFsqDypWmsPwybcoTlxE6ggOFU9ZEKk2kNJUkBGBq7du65fRZ2qqQP4cxE6aa7rYaqUN6uV4kas6Ep98hvx8az+W6giI0140K9ZB0P5QqzupTnsgwLwi0pO+5VdJqUR+yGAuZZoiiI0SzhBVJWKSQBHdVUNspWviDO8w/49YopRZVVI+9mXWwgycxoA6jksYVkU+kObW2isJSKeD5CvaJkw8HmZiEqp0jkQ25kNbVe0NcePJutMQNaxc3d0saKNnQgbz5AMu7dCGSsbURu1ZfCrZvUCuGsDWhqsKaYO6IK3SklofMg3VPk242s88EsvFcd3TwAvKGSczwQMCDFH9vBX9HWvQwkFjvQFIuuRrzacbNW4qWGSwqWscYBaN9G7tqspD4kYnvsLuAtl8ieI14uJp0uGSIave0G7zOi6o0iLsHmUwdGQtTG8lEGUNZOPtfhJdBiPyslLu5oH5zkAx3kA19tH2Bm/8vsCIcm1TpYzi+SlMmmTXxqWXiP/v+MrA91qPCTQjysQj+DrQgMaVlxjvIS0koqErtfAjJ7FMOdqAPW6JycCv18qv/iLvBguBAJ+kNXQvwPxvOEZwslqDTB7ACaPwCZRvCi9CA2+SDLsACBtQDSQjNwhlSr5v/jIvoJjKSxCFPEQTk+yspVbUMdlQMQHnDXnNWbbNMpFNg5wNxQEnVdrvFXZmFS/lSMSmZV7CUsqD2QCm9aYiCxTtcW5etokEREnl1gouMcFNUybAFyuNW74tmyaMPKyxyoSxbfYjXv3m1gSOeuDI5o0oVr7mLfElCTojDWNjFWcm4MjE0S4nU/wEFm/NZYblU0ZlMJlt1CaN4DrQwiX/hWjU5i2JAHLiaj80qiv16NpE5WY6MRriQC1iaF6x6hGDBP0qz1X1hGFo1eRA8eW4J4lSx+eUjeWMTnZOTgEz5LUwEDMHRtwQ0IwO8ABrkLO+k+iQagmzQAMIB+zcT2FKFfT0Q3zak0fEaJpWJwENzrQm6CV0M58QADmTj8poszTTlQkEqYBK2pImcPGUqDCXJ4huHcRIcgq0W/eIkzY/zzwjqOlAcwNgaGxc0EWrc/y4Q0DRqyVLhzXzjpxSsE+WAEEbADcEEju9JJPIw1n4Dj4Vc0l2sBBrAsqojC8ncSWJY+LKZvMssERpavXQL0hoaZPib0ghj1FfwpXurKou/8CFPnWLgOXZovGbwgCfskywPk3wKIALSVWbNiVGheue9gGsbE6gDioSSxPyuBQ+pqpUTPVS9xGuyvLjyOpOsElPSw+Y0gaWljUHni9cuoBTA87cRK5UT/Rae2lSRyrKJHVIkXWemiqmOtDtJQD9vOONYltfg09MJTZE4RFe21ClktRk5zJ06oxON3MJ+bVwtNNOjeezSnBZjSn+MFC7VNKO2ra0Nq1xktu2PsQ1S8SgMqw9X5WTYA+/iPMK3DPL5KzbVA703MdSVRWpnvXeNSs996dyy1M+L3f3iARwb7HJxOzJekbmwJ5k7GPFXtBOJbSboa9D83aQBlogiURhTv90v85GduZjDE0TgKdzyIb0/EwsCjkMOu9zKUz3ZAROC8N0fuNReiPtVNX2s9CjTXL4Nrs2BZ2NvF6CWvGGDnnFLbOymY5rVa4Q4vrQ2R4t5rosz3hUD42xYlMu3964wmB19TLZDNhIk6CuU7ZQ2JzTR/2V4G5qqZJ40Yrr0sItBfUxYMESPuY42Qb3P0t5QzBGAnDjkPu1ibf49f2QksNafaOAjddQlVAuidfP24ZhW/sP4sKKLNPNKLdm0qj542yg0ZE4sS4jmL/D5jwlhF7MUhaAjWojio/EhgexVvfwElhRFelPJN80phE2HLB0ODxjOlY6HEz6LkSvDeAwDJD/kRCcOn1zMExCWxxIJxCXGZpXZMO4cBikuqhj75M9eph1+vUq7yvuuq8bNvTmetA8t1rYcAAj3k8ao6y3Qq0/EqxnTGEH+8wcuwxk4U1AewyH8KeUOjBKu8YGJAsM5M+iwDISrzCGu/6aBrQ7e0Nbe7W/gEgWz7qjgPoq47LfsL3nbjTkJAUNgLvXhsCfDL+zQbqncSSh38Kbn7y7QAMYLBlbT7m8S1e4s1ZyZlZ6pbuhIRdT8WdKfGyaCY9sRS2LDYqHh4ISecd/h9MIx9smACzHVJF/+7BndQusZrRyJTLFJh9nySzB7WPgCh6b8XB6hS9VPFwJbo5OedfISZQv/2WujSbRRzHY9CU5aEOD0rKW/7qHRYPTLAlYssoGtXBGI3dTcRCKKvTbmBJHy/RuczPZE4BEQylS0ZOHYusfOV5NQ0/mtOc7fafptM6mG3SEdvi4n8KLfvR5rmc/2/MBFangM66LYPN1OvOCI6lTEUbAc2iK3nMLD+m/amtgilE8Wz4yZ85/Ln66jITsTjjCQ7qG2YbruzVs9PScG6o7hGmn+kGZSmof8M9BNDVm1z5YzrVqcNRwj01IyWhJfbrOTLZE4ayXhvbAAnaz2zwLkCpZh+vx13XtS3cfyHkhP429ctTuL3/uRxWfXvWutjWf9uk7pDXWWvYsRO4B5I5p3/8S7PMvCADiSJbmiabqyrbuC8dyGszoEwhiIjQNsAgQCDVAIjEKGgaC4ALQGAAOCBKztDg8R0IAojDVCWo+YFfU4BUMIidU2nWAmUGCidjWkroCKUAoUMDAUKCDcHBAYBDwACAHcCVwwGDzRzMjZ7dEcCA2ebXIhpaAV1YnoEApgleSRtInUoAQOFjoFpUUYNA5YgootYtQ6ldyBYU0AvtnB8srSVlQIIUQQKmAdFbJpc3d7f0NHn4JLhkQMKCoYO4AwHpEZI50lWCuIEVQYD6nUzIWv+wFDLUA6gAYUBeA3QB9TxYGOADAn4In5gIUsBOp4pZ2RSJWxMbMTxeHA1T/SRPhMBokHQ342ehoAiYMevEMcHpYBZSulAvwLMinzk6DisJkGkSoS5ksBuoOFPJIsOfHdgfMCTi4DmqAH3iwbrXCz2tSkSGp4hRBTRPCAiC/GRUHN67cudze0r2Ld4+dvDEYTNJm1xLfweKUESYc+LDixYxLJG4M+UW2yHADP6ZM2TDmyps7e457+bPo0d0skz6N+mXq1az3tH4Ne9yJ0LFrR6ZtO/dd3JvxaFaxkJjuE8ZM+JthuhK8vXg1sxp+G7r0w7ypMx/hW/idGg/+vmD1G8VzLtdXhAdrojgJBpNhJI9xRYFLutlJjJ+uuDr+/TL0R67Pwnkq3McCgTEI/wjcfLlU8t4MiRDmnH/8lTZhheJIiIJXSBxiVSBVpQJFPZQM9dAyi4iY3SJ2EKEKRycGUIUIHhLEwIup5GMRLPiYkxNCSOAIBnkLIPTDCAMFkMCLyIgAI1tMMOAQRPMoIAoAOJJSFRUrDRDkbLLBwARNXVrJkFY94SjAjjA6ohGHOfhWwIcMdOWjhXRhaGeeTIbjyi4LDMCOjIIQIgAq1hS6BnkjLPJAfUcYsSRHEWlHC6GLMgKeFFp2B8k9uhAIiAIqUMNAeF+txOIIYWrHCi+HQEmlCg2+cEV7IxTgQB0j8CLCphAxomqgklZaSClI+KknZ8ku6144OPJIgDoDLP+gzABHVITko0I6BGN9nIRiXw2/VZvAn0Rl+qI5S+gQCqiKDKVAjGghZYCpe13hwEM6DIBIlavUAO4f664wqwu1XscATUh+cako6SaVTwJzSivVpCiRUsOzazLrFsceE8xnpL3wAAwVhiaTKJMEJCAqe0VZDIkCRWInLqUlI8AyAC6n2oy8Kxn0aTWOMRcICbgCgEO9og6NkktKAJpAyv/26gmUCsb0Ja06TEYqANfoSvWuPos9cn3BGEuCih8zuHbbjoUj1hIM+XMqiWtGucxN+bysDA7lAZhMRVxVtTdTOd4D5M+hGD4mIES9oo8uWSCpV9PwUD5PARuxcpOW6nn/iYJ/B6e9FhJ091TVm0D6JSJPvgkuadxqux0DnrQPZzsMCGqzu3Ha3R561sDTnvvwsRXvQu8z7NLIC8oDX7DxayMvPWvUVz9d9Ngze/32pHXvfW7ah58n+OR31n1wyf9+PmLCdwM4XAa6VV6B5ksq1/3tRwdOdy2ioIzn9YN9/dmLrW43PuBg6281A8fo5gemqwEEBvHzBgQptL8JXU95ASRgXg5ovASmwFopqKA3unDButRvBSlUjv70l0HGUO9FaQnIlrClBqCMCEVC2JjFBlAnsQhFREMyRxoqojaSzIkgD1kAlMwBkfJlbSArVFWklOitLCGAPRuZQvOQFsU2/1QjTERhoh6SQCSoaI4IREDAFYBEkeswgUsKq4KaGtg5Oz5rUmM4kuniRCMiNOUJ+TJHF5ETQ/5sEBhdYBgQ2RDANfhlFiCSDxEUBIsBeMoADVhaqA6Fisoto1KWHAnG/menWaVuaSjgFhMGVUqLuWoS8jGALLKwngAs4Av1+sEDTfkKVmaBkA24ZNOMxo7JPJIEOeNFfWbpF3bA6TqkIlaagAmsEyZyP4sEmh0cyY8OxgJnOCRQJtmlC1moTGFI4iRBqnAGIWhLABjbARLyxatUZm2VwFnSPOvZh4DpwgFpeEAhZiYC+cQrAS35GQqLoC0RuDNeR7LIc56ksLaoKv+cqVuDLoY1AIGCC0AIoBe53PFHJKGyP9vETzf/kJN9yGhpSqFki8wpBZ1w8genAFE/wJBNQAyqWBBdkhKkGDwSULGfKKvFNWVZtSyAoQH5lNEBkICIhmytESg9QSCGSbONdu0aEzwmoxwBBmc00BmTUCvMjpY0WJytqCTQEmBamr1wBLAeMgVCVUg2zhBByyjnBJoBfmKRLthtFo+jSRLNURKUXk5kGnwfC0ioKsgu0WJ5DFvSsBCHIM2DR3QNHI+0Us+meYUtZf0ZJPQhkHrgUYteiBzM/JGPesEOpayjUV3wKh0YMuaowN1GUotbiaKpQIDaRK749nM5CbZUhM7/9SoUq5gMDyqrusfjrj6P613dCDe8FyJvZcFr3u6mdzXjhczo5PI5cmg3f5Zdb2raa9+7zqAcW1kp/piLltSNLVwV+d174ddA17rQq/MFTX0/E99W8iPC6ZHusvCbX9XIAAdVOAhCw2oDB1RBEiX8qIRb641qWZgbAO4Yek9D4QrDZ8V6wnCGWboeaamgAcIKQqkAeSN96Ii2gdDhCTjVqRIQoUqdHZ0SCRpMEsiHBDxe8keA+A8SFFKXGuIjjGrgR5i578UtqCObDGm0MjHRhyjRLDXseSRqIKQKdYxzRixCkTnHuW02vnGzIGeOL5rgKRKFmFMzFQYvTCIQBpik/wls2TxNKnmB0DwYKQXAqQRIoaEjgDIJtQAgSS95D1/skxYCsSKYVLPB28VaJXKWTRQcLQcRGdOl3wwp19KaxCPImTHooAco77qvfPbzaGRCN0G3osfVOGkRAmrisQSWBFkYcLgcFu2ByRMZ9GTPAwB1iC52h5KcCjU6/RUIlWpsFn7AQ0mR2OLmgu5AHa21SkeQsKk0ckz/xPWjjPHQetX71wKoKFC/SezpGVs0MjGcdqnRYZlZbK6UaEbVavoKzVmBVSZO9DMsPVSWUCELYdzVAQTOFXEtTacnoIIrsjs1uEqbOg/OELAeQTa0CI2s+874oXVxEHkEKrRnfQSgmv8GVkU5UlgKX7hnJMTfBlQcdowb8lkwfits5YTjTKatkzUbkb+QtRVScJmkJqfpc+N7lTUyabvFFbl6sbq8ZL4sbHvr06Pooy0MswLYF3IAsg7kSBd5rUViC6M7U67ngy+209En38fjhboMx25x+yz5mutu7pnX8LxfA0LkYr7zrib9fTVvepqnXoarRw3lW/9B2OdnLjHmRu29+/rhoSKU55X9YPR34G/cvjHDl5EfnhdvHH+eVsiYHWVaOAMuCo0uxQfH6FsPfBpXovqKqX6Lk1871Ken+aE/DPRnkIAHpP8u3Je372Mvgz6MwUY7tApAlChYWjcpamqec8z+4Sb/82FmW9ZFcPQH/gdoE6E2X2BndeJHSqIjOAJPc6YkdzJF5mB5mKUi9PcUfvEAXbYH/mdmc7QGdYJllANHaXQr51ZEX4Fbh7QHV1IPQCMi+bc1/qcmCLBn8Pd+PKg7hXcpD8BoDkUAlyYJbFArHzZrnpBkS3Z0KQBrylYCS1hr1KZLRhBSPfdrPHWFOlcqx6cpVcApwyZmc6FKMzhC2JINjFI0RWNqXbRrJedrsfKGohY0M3UCTxEKvOdXxEQDOhA1BuB8bHhyDiUGaSWGUqJ94XB9q+cfymAuPKItB/NPk7g1dpBv/xBwOhUt59BF/AUG6SYx+JZRANF3aBEk+LCA/30FcDrodsb3MKtYhvSFXvw0QuRHAJEII34RLVWwbpWzZKDoWuvGiUUwUT6jh0AHLzqILWPCNMogBLqIM8gwOrykhgPzez3IF4/oBznjMtY0SiEHjo20c21hdGo3CkGIVnUlL2PFd2NyC3AQU5AQKFeQNDKnNMY3BT7Tc3xYVdZ3geWngfLUMmsSNX/xcjFhB3JQdH2VkIoTNP+jXBfjEVXyVWckK2WxDN4II+OIcPtoBUw3edrog87TboSzi03xFCOhWYaTIwCxWtigDxhxbjzhd4eHdy0Sk6bojBLxBBKBeG5UEWIQd2gXgfrAk36FJFngXxi0fAaDi3qzJosQFv/0sgczaXgqYQxxo1NV9zg0w0S6dVp0Q1mKAo1DgJJbtBaXaENqEpTbSJIjCRmEYG2iBBvtFwMOsIiIVHeIYXnTQZfHFpe70RgFxgLlRxp4uRm5Z4Z/iTuQ9T2DaYGSCRmMmRv40JQhRJm0uJmLYZm1kQWdlJnQ05mtFhcR4jGTdABSeBqfuRqdwAhZoJHe04ipJ1yoWXlx4QAOkAAiCRfgV3rBiRkA55h3UAAG5TUucTS0WZp0Nxe4+RmIaQMHcRB3AZxv05eMoZhaJgB66VezuT21aXr+EWZF5lt0IxyC1ERkgmeHgIckknf/RznlyQS6AJ9LNEgKE4kl528Sgzf/OThCOMIlD8EGBoie8nksPlKBv5WdI1Qn8mefIuIVDUB//RlnLHkOlLBmVUCAJhCa8Yk94kl6eFJNkjRyfJCewHQrDuBoJlNJ8zEAXLgRJcoML8pGkNAWqVIC/amjIIlkxDENXUBosZArwJJJm/SG1+kaDdpKMopqEfGiuFACjNKfulaEsLQ1h/gHrIkdIBqizcmIM/Bu6lJTfYebR5CJlNMHyMlOV8QPMDKmM9emXXUG+DQfVWqnsXhirIBRH2GmOXVu66akxvWULdCKytCm6tQG3MKM9mSl/5SUojia5yOinecf+FhT8RgucFaOQPMUJyNj98gOcXV8eUengkZc/y4SdLkQDJelA3xacOWoqTr1kHzIoIXqqkgzc6D6Br1WkEUhiGT1hELlVEmZc3hVqZn3iHGHcTRhD5sKKTtpBN6xWDe5a8xKDIvVVTQRZn4XeBjzD245Qq9aBEywk2ICqIYVN2jnlMJpMEMpZos1oVKZEw8heKSFEWC3bzl5eWAKkLmxnbHxkCW5pDPmr4d5sO4XGwHLGg4RK2OGqyvAsHGZrJJXsdS3l9LjmgmLsByrX3oSBYoaQxvrseJXshGrG2mgAOygaQYBhBlEsjKgPrYxqCBGGRfrdDgrTn2hBbqAA0YyffuzsXRDoSzgPyh2Goj2DecnlyerfJtxnd/2AP9F0rK2VJyayaQnIAdPsAkBwnmdobQWlKw4u3CPCGRL1EYvaCZmlowQeA9eVyct+GFowCV1GT6zslQpsJpKBrc1UUZD0EPUIIMEUQwOOBUBKLfsqXEHCqBZlyPR4Fv711ltK0TqiZGe6bR8eSAhZ0xgRVBgw0yi0rbiVGmbZKvEYbd3u09oGDr+kmivYodypzLG9AeAuAbOBwkyCrRQIiynS6RB0Ag9A0bQymiOdirQ1LadNLsqynqZG37x5wfWwgoGd4phh5SjC4YipVPHSF5nSLh66zPae25n+RwoqjLoAVNxahMUc4xpmgB/qqdT81bwpAnZ1raKKgRdVZjO+7z/B3IzrJB0ZrAXDYmjFcl7Fhd2VmNYKNO9AWl5mWAQ6MBWCryHZFG+GqlMOiCqulolCRkI7qipdjVpFecH6nQGE0xC8+cLgOuo+8u/krFfu9URZGkmKQEG8KAOh/VXVuc54/uVuGeyJZBRNuF142vBHWG+rcUtRJlYcoNndIMA56oPiIOU+KYOhVDC9LsKtIXDkpMP+cDCuebCL9wC3EjGEUu2JyYOA3sXqYoZaexnZnzG2ImynjGxxVAPrisX0RWdc9yxfnyr7grIsdBxhDrIgnzIMJy1/MsJQ2rIifzIkKzIdawbTBsDlqyPcZFCRzCRkQzJcAx7rhlhxUdwJxTG/5g8G/WDyoUVDhfEHgTgbXQsyXsyy/2LyDZAyhlLQUWAyi6wyl+7y8sVJC1bsLWshseMzMmszMvMzM3szM8MzdEszdNMzdUcxBt1gDwSZwC6ZVBcKzgogVqGUKEkBEBiuV0UgIKVCmz0ZYpQEessE/tnoIZ5ZxOhFYBat1MxI/A8SE9UIoQ2ap5cywMdyFpTu1VoDL6ypdhsiFWo0COQaZt2iZzDvPSYDDZKa2XFKPdxKiuqK+fkBpoGvD/0sF5oTTcqvdN3OfAq0ATt0k9r0FqITthSLxGjwEQYEPGrM4wAbnqQv7xcWqtAMXOKxLnIqByNiRn1pyvRd/iw1Magvv/O5qh2+scvbdWaG0FJ+YQizI5PWI2IiAJUhQAkt7yUoL+twAOmWtQc+TKVA8JXiAt0ANfTMtfDOKrSNlctbAZ6LMtX7dcuIDpsyTCD55Y5OXhf3Q6J8wpihwxCwDhnnZVPoK1FTa9IrXcWgQTOmq4+aQRT7Fq4lRQybE+TVdV/bdqyEpdsPED/etqtvchO57B8/QrAjNqubdt9bdWgfNvYd9q6vdu2GRu2lNG+g6y/vdv+gUSK4QDaVbN5cccKa9ymLSHSGRecBkC0TZrR7doykbc0gBF1Yh9oEmbpfJ8JuEvJLQIEyMNb1IW9ImgbuiUlmBWVG7gv6M8QQYD13BD/4D2Z2t3bJWCL3t2EhfyPtcW7F30oufAELfs5sYbAr1JLt1RyB01iy2QKiaC8eUNrnltMQRtrcr3gObVJhOnf/11XrBs6NLnAhVYl6tuJ09KmRpKKCWdvEgNtojBQBXVQTOOE/KCoA8CAy6tzFQEGVC2pTNDUMhUwZljiJg60iDkS6Bg2RMrBI8OrCt6rFGYymhJVTgEF/xharrXCKwzAlytGVUIFIJ7lalfgLtbkfo3c6sJy2JE6hRJ3NlmtpmXP6pGT6+1ZhfwHWLmVCMEOiAXGz0GWk5WT+g2ROjypbPPmcF491G2Fsh0O3smZkf7Svv17V8vH0MHpmp5hoW5s/6Qu6utl6jeW6qfewKp+tZXJ6i696kvc2Y8zpo5seA9CNzNtf3oDgxlJHG/66pke65I860hABAsQURwRTgTkAKykqzVC4Drw7O6xQs/N2sVu7DMwoOeQD4UIR8T8hLFwbuRdg1bUK9NIZWVpArUKBi/ChWYNE4nL2UJgoX9reCWRzWyW72jL75Os7Z/M7UFqB46MK6Gw5FZSk737olawIbrATl9ArhZhAoKLbZORBU/lIheN5S1r73RFnJdG4baGpbTreQGfyIGNP336D0zAm1N4bi+u7DhkrXQWKQlZvRlX6WDhY/gjUcuY5MtQpcQJqT3Xa9yWWpCO8inP7eTaNP/umNhmnsIdlwZXju5HTwI4ECidTJ2OICV2gAPUUugPwgvVbhyaU9c/HaxCpzIeaUNNRSi9XMxLD8gqD6vS+qyTFpZ4/sMF3Gta5wVruR4kUni7nthZYRYaZ1prUu/5+q211c79bqyZlaFy39J0z7/CxYubueqYP113YfaU2fmen0ijj+qkX/dOjvpknD66fEyjbnmmv/qU6g2lbLAF5POeEbYG4/qWfc2z35nFY/tZjftJiyHPXX6yD/zMKQN51ID/0GUQWiVvxBBE0AhkFe5lpPA6s5ogyAX+R4JddoIP/w/S/86EIGRve3WQm3fbTFuXwkOXnfzL/8L+UWkThqT/x3JqL/v6IAAAhQM8RzOIKwkEBEAEgFDQdpMAxrGsroB2AAwUBkBu1xs0AIuAT4QIMGqwlSHwkIkEqkMQcagWDIwD4jcIAsAAMeMnym5nKdFLLp/p+/4/YKDgIGGh4SFiouIiY6PjI2SkpAti1pGLwZqIpmVBwGcAgpfeGkMCqA7AaZwpqgsM1xmBQponaNpKnkwmm+0ngqYLAoICqMGo08AtF82AJd6xygjuZtAz5sqC8i9XAW7eH9/kOHm5+Tl6uvo6+6G4oZvA2EAJkXWAQdIKsprAVJwCHQ8KDFDxD0BAFw9i8ElQYAySVHryOLARTF81E/haPMCHLIECAAxC/8mIMyreGGTe1NRDGUcESJEk7TR5csXPu3Y6d/Ls6fMnUJ05CRE4EADNm1+c8Bko9ikaKQFNPxVIIGMBg6pTA1RV9YtPFjZb8f0AVQBGsLGZQAURQNWjtKJcQzEoVmCUXKQqqSUlaRTpCrmeEHBZ4KnYzT5DgzJu7Pgx5MjjFkuenBhQsMqNKGvu7Pkz6NCSOItWBE5Q5tKESKtu7fo17KCsY9NmN7s27ty6dwe6zfv3ZuDChxOn7bs4ckDHkzNv7rzc8hWpn/OOTv069uzKtXPH0/07+PC5EmkK4JSvDLs+bBXAum2IA1ALpnzSMRZGg08KXop31/8/gM1ZZw8QN//8cBUSTbDgQEm5LCTHPw2E9IoA+yHERoCDDJghhx1WNmB5MCBgQ2B81NBKfQDEF48nCTBAjDErvXKKKx5uZyOOOYYGYhB5jHggHwEdlJAIT1zSxogldJRPTS9UyJ+OikU5JZWO8fjKGySKIIN+BmxVFZcBuGiUeVW8ZYBhc+F3S5XjtfkmnOtsGAgzkhgZ5x546rlnJHMCUqcjYWK4p598GqpnoYfulKiijU7JqKPqQBoppRxOWil0mGp66KWbjuYpqHGCMiqppZp6Kqqpqroqq626+iqsscpaaqi12norrrnquiuvvfr6K7DBCjssscUaeyyyySq7LLPNOvsstNENSjsttdVaey222TYXAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If magnet might be or is known to be a high-powered type (neodymium, or \"rare earth\" type).",
"     <br/>",
"     &Delta; Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a single view and be misdiagnosed as a single magnet.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     The following \"magnet precautions\" should be for any child who has ingested one or more magnets: Remove any magnetic objects nearby, avoid clothes with metallic buttons and belts with buckles, and ensure that no other metal objects or magnets are in the child's environment that could be accidentally ingested. Maintain these precautions until magnet has passed out of the gastrointestinal tract.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20032=[""].join("\n");
var outline_f19_36_20032=null;
var title_f19_36_20033="Exophytic squamous carcinoma";
var content_f19_36_20033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exophytic squamous cell carcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A whole-mount section through an endobronchial exophytic squamous cell carcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20033=[""].join("\n");
var outline_f19_36_20033=null;
var title_f19_36_20034="Annual Lyme disease rate by state";
var content_f19_36_20034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reported cases of Lyme disease by state or locality in the United States, 2001-2010*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        State",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2001",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2002",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2003",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2004",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2005",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2006",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2007",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2008",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        2009*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Confirmed",
"       </td>",
"       <td class=\"subtitle2\">",
"        Probable",
"       </td>",
"       <td class=\"subtitle2\">",
"        Incidence",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alabama",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alaska",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arizona",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arkansas",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        California",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorado",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connecticut",
"       </td>",
"       <td>",
"        3597",
"       </td>",
"       <td>",
"        4631",
"       </td>",
"       <td>",
"        1403",
"       </td>",
"       <td>",
"        1348",
"       </td>",
"       <td>",
"        1810",
"       </td>",
"       <td>",
"        1788",
"       </td>",
"       <td>",
"        3058",
"       </td>",
"       <td>",
"        2738",
"       </td>",
"       <td>",
"        2751",
"       </td>",
"       <td>",
"        1964",
"       </td>",
"       <td>",
"        1104",
"       </td>",
"       <td>",
"        55.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delaware",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        339",
"       </td>",
"       <td>",
"        646",
"       </td>",
"       <td>",
"        482",
"       </td>",
"       <td>",
"        715",
"       </td>",
"       <td>",
"        772",
"       </td>",
"       <td>",
"        984",
"       </td>",
"       <td>",
"        656",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        73.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        District of Columbia",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Florida",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Georgia",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawaii",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idaho",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Illinois",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indiana",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iowa",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kansas",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kentucky",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Louisiana",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maine",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        219",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        247",
"       </td>",
"       <td>",
"        338",
"       </td>",
"       <td>",
"        529",
"       </td>",
"       <td>",
"        780",
"       </td>",
"       <td>",
"        791",
"       </td>",
"       <td>",
"        559",
"       </td>",
"       <td>",
"        192",
"       </td>",
"       <td>",
"        42.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maryland",
"       </td>",
"       <td>",
"        608",
"       </td>",
"       <td>",
"        738",
"       </td>",
"       <td>",
"        691",
"       </td>",
"       <td>",
"        891",
"       </td>",
"       <td>",
"        1235",
"       </td>",
"       <td>",
"        1248",
"       </td>",
"       <td>",
"        2576",
"       </td>",
"       <td>",
"        1746",
"       </td>",
"       <td>",
"        1466",
"       </td>",
"       <td>",
"        1163",
"       </td>",
"       <td>",
"        454",
"       </td>",
"       <td>",
"        20.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massachusetts",
"       </td>",
"       <td>",
"        1164",
"       </td>",
"       <td>",
"        1807",
"       </td>",
"       <td>",
"        1532",
"       </td>",
"       <td>",
"        1532",
"       </td>",
"       <td>",
"        2336",
"       </td>",
"       <td>",
"        1432",
"       </td>",
"       <td>",
"        2988",
"       </td>",
"       <td>",
"        3960",
"       </td>",
"       <td>",
"        4019",
"       </td>",
"       <td>",
"        2380",
"       </td>",
"       <td>",
"        883",
"       </td>",
"       <td>",
"        36.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Michigan",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota",
"       </td>",
"       <td>",
"        461",
"       </td>",
"       <td>",
"        867",
"       </td>",
"       <td>",
"        474",
"       </td>",
"       <td>",
"        1023",
"       </td>",
"       <td>",
"        917",
"       </td>",
"       <td>",
"        914",
"       </td>",
"       <td>",
"        1238",
"       </td>",
"       <td>",
"        1046",
"       </td>",
"       <td>",
"        1063",
"       </td>",
"       <td>",
"        1293",
"       </td>",
"       <td>",
"        667",
"       </td>",
"       <td>",
"        24.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mississippi",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Missouri",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Montana",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nebraska",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevada",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New Hampshire",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        261",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        226",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        617",
"       </td>",
"       <td>",
"        896",
"       </td>",
"       <td>",
"        1211",
"       </td>",
"       <td>",
"        996",
"       </td>",
"       <td>",
"        830",
"       </td>",
"       <td>",
"        509",
"       </td>",
"       <td>",
"        63.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New Jersey",
"       </td>",
"       <td>",
"        2020",
"       </td>",
"       <td>",
"        2349",
"       </td>",
"       <td>",
"        2887",
"       </td>",
"       <td>",
"        2698",
"       </td>",
"       <td>",
"        3363",
"       </td>",
"       <td>",
"        2432",
"       </td>",
"       <td>",
"        3134",
"       </td>",
"       <td>",
"        3214",
"       </td>",
"       <td>",
"        4598",
"       </td>",
"       <td>",
"        3320",
"       </td>",
"       <td>",
"        392",
"       </td>",
"       <td>",
"        37.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New Mexico",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        New York",
"       </td>",
"       <td>",
"        4083",
"       </td>",
"       <td>",
"        5535",
"       </td>",
"       <td>",
"        5399",
"       </td>",
"       <td>",
"        5100",
"       </td>",
"       <td>",
"        5565",
"       </td>",
"       <td>",
"        4460",
"       </td>",
"       <td>",
"        4165",
"       </td>",
"       <td>",
"        5741",
"       </td>",
"       <td>",
"        4134",
"       </td>",
"       <td>",
"        2385",
"       </td>",
"       <td>",
"        1040",
"       </td>",
"       <td>",
"        12.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North Carolina",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North Dakota",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ohio",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oklahoma",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oregon",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pennsylvania",
"       </td>",
"       <td>",
"        2806",
"       </td>",
"       <td>",
"        3989",
"       </td>",
"       <td>",
"        5730",
"       </td>",
"       <td>",
"        3985",
"       </td>",
"       <td>",
"        4287",
"       </td>",
"       <td>",
"        3242",
"       </td>",
"       <td>",
"        3994",
"       </td>",
"       <td>",
"        3818",
"       </td>",
"       <td>",
"        4950",
"       </td>",
"       <td>",
"        3298",
"       </td>",
"       <td>",
"        507",
"       </td>",
"       <td>",
"        26.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhode Island",
"       </td>",
"       <td>",
"        510",
"       </td>",
"       <td>",
"        852",
"       </td>",
"       <td>",
"        736",
"       </td>",
"       <td>",
"        249",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        308",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Carolina",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Dakota",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tennessee",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Texas",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Utah",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vermont",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        330",
"       </td>",
"       <td>",
"        323",
"       </td>",
"       <td>",
"        271",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        43.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Virginia",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        259",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        274",
"       </td>",
"       <td>",
"        357",
"       </td>",
"       <td>",
"        959",
"       </td>",
"       <td>",
"        886",
"       </td>",
"       <td>",
"        698",
"       </td>",
"       <td>",
"        911",
"       </td>",
"       <td>",
"        334",
"       </td>",
"       <td>",
"        11.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Washington",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        West Virginia",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        6.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wisconsin",
"       </td>",
"       <td>",
"        597",
"       </td>",
"       <td>",
"        1090",
"       </td>",
"       <td>",
"        740",
"       </td>",
"       <td>",
"        1144",
"       </td>",
"       <td>",
"        1459",
"       </td>",
"       <td>",
"        1466",
"       </td>",
"       <td>",
"        1814",
"       </td>",
"       <td>",
"        1493",
"       </td>",
"       <td>",
"        1952",
"       </td>",
"       <td>",
"        2505",
"       </td>",
"       <td>",
"        983",
"       </td>",
"       <td>",
"        44.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wyoming",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         US total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         17,029",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         23,763",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         21,273",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19,804",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         23,305",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19,931",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         27,444",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         28,921",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         29,959",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         22,561",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7597",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7.3",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Confirmed cases presented for all years except most recent.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Confirmed cases per 100,000 population.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Adapted from: Reported Lyme disease cases by state, 2000-2010. United States Centers for Disease Control and Prevention. Available at:",
"      <a href=\"file://www.cdc.gov/lyme/stats/chartstables/reportedcases_statelocality.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"       file://www.cdc.gov/lyme/stats/chartstables/reportedcases_statelocality.html",
"      </a>",
"      . Accessed on March 9, 2012.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20034=[""].join("\n");
var outline_f19_36_20034=null;
var title_f19_36_20035="Narrow complex tachycardia";
var content_f19_36_20035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Algorithm for narrow QRS complex tachycardias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 714px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AVNRT: atrioventricular nodal reentrant tachycardia; AVRT: atrioventricular reentrant tachycardia (due to an accessory pathway); SANRT: sinoatrial nodal reentrant tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20035=[""].join("\n");
var outline_f19_36_20035=null;
var title_f19_36_20036="Phenylephrine (topical): Patient drug information";
var content_f19_36_20036=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenylephrine (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=see_link\">",
"     see \"Phenylephrine (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=see_link\">",
"     see \"Phenylephrine (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anu-Med [OTC];",
"     </li>",
"     <li>",
"      Formulation R&trade; [OTC];",
"     </li>",
"     <li>",
"      Medicone&reg; Suppositories [OTC];",
"     </li>",
"     <li>",
"      Preparation H&reg; [OTC];",
"     </li>",
"     <li>",
"      Rectacaine [OTC];",
"     </li>",
"     <li>",
"      Tronolane&reg; Suppository [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat signs of hemorrhoids or rectal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702730",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenylephrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703538",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A fast heartbeat or high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rectal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding from rectum or rectal pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use cream, ointment, or suppository rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695758",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take foil off the rectal suppository and put in, pointed end first. Do not handle too much.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699309",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect suppositories from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12288 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-31B8A52DC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20036=[""].join("\n");
var outline_f19_36_20036=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024564\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024566\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024565\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024570\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024571\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024573\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024568\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024569\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024574\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024575\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_36_20037="Proximal phalanx fractures";
var content_f19_36_20037=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proximal phalanx fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20037/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20037/contributors\">",
"     Rebecca Bassett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20037/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20037/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20037/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20037/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/36/20037/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the proximal phalanx can be complex owing to forces exerted on the fracture fragments by a number of muscles and tendons which often result in angular or rotational deformity.",
"   </p>",
"   <p>",
"    This topic review will discuss fractures of the proximal phalanx. Finger anatomy, other common finger injuries, and thumb injuries are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal phalanx fractures are often unstable due to the forces exerted on the fracture fragments by both the intrinsic and extrinsic hand muscles via their respective tendons [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/1\">",
"     1",
"    </a>",
"    ]. Anatomy of special importance to proximal phalanx fractures is described below; a more detailed discussion of finger anatomy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the lumbrical muscles, which originate on the tendons of the flexor digitorum profundus, and the interosseous muscles, which originate on the metacarpals, insert at or near the proximal phalanx. The lumbricals are involved in flexion of the metacarpal-phalangeal (MCP) joint and extension of the interphalangeal joints of the fingers. The interossei are involved in finger abduction and adduction. The extensor digitorum tendon runs along the dorsum of the proximal phalanx, while the flexor digitorum profundus and superficialis tendons run along the volar aspect.",
"   </p>",
"   <p>",
"    Proximal phalanx fractures often present with apex volar angulation. Interosseous muscles pull the proximal fragment into a volar position while the distal fragment is pulled dorsally by the extensor hood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the proximal phalanx are caused by a direct blow, rotary force, or hyperextension of the phalanx [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/2\">",
"     2",
"    </a>",
"    ]. A direct blow to the hand is the most common cause of injury and produces a transverse or comminuted fracture. Such fractures are often unstable because of the forces exerted by various muscles. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Twisting injuries result in oblique or spiral fractures. Intraarticular fractures of the proximal phalanx can occur with MCP or proximal interphalangeal (PIP) joint dislocations. Avulsion fractures can occur with tendon and collateral ligament injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with proximal phalanx fractures complain of pain at the phalanx. Often swelling and bruising are present after a direct blow to the dorsum of the hand or a twisting injury.",
"   </p>",
"   <p>",
"    The injured hand should be examined for deformity and gently palpated for focal tenderness and crepitus. Some degree of angulation, shortening, or rotation may exist. Examine the phalanx with the fingers in full extension as well as in flexion. Although pain may limit this assessment, the presence of weakness when testing motion against resistance may indicate injury to underlying tendons. Comparison with the uninjured hand can be helpful.",
"   </p>",
"   <p>",
"    Evaluation for malrotation is performed by flexing the metacarpal-phalangeal (MCP) and proximal interphalangeal (PIP) joints. Normally, all fingers are directed toward the radius and there should be no overlap or rotation (",
"    <a class=\"graphic graphic_picture graphicRef73269 \" href=\"UTD.htm?39/37/40528\">",
"     picture 1",
"    </a>",
"    ). Malrotation may also be evaluated by positioning the fingers with the MCP joints in flexion and the PIP and distal interphalangeal (DIP) joints in extension (",
"    <a class=\"graphic graphic_picture graphicRef71612 \" href=\"UTD.htm?38/20/39232\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The neurovascular status of fingers is evaluated using two-point discrimination and capillary refill time. Although values for both these tests increase with age and certain disease states (eg, diabetes), normal two-point discrimination is approximately 4 to 5 mm, while normal capillary refill is generally less than two seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior-posterior (AP), lateral, and oblique x-rays of the injured finger are necessary for evaluation of phalangeal fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56068 \" href=\"UTD.htm?13/48/14081\">",
"     image 1",
"    </a>",
"    ). The lateral view of the injured phalanx should be free from overlap with other fingers if at all possible. Overlap creates difficulty in evaluating displacement or angulation of fractures, especially at the base of the proximal phalanx (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83503 \" href=\"UTD.htm?24/49/25364\">",
"     image 2",
"    </a>",
"    ). Radiographs should be carefully examined for rotation, shortening, and angulation.",
"   </p>",
"   <p>",
"    Fractures at the base of the proximal phalanx commonly occur in a transverse orientation with an apex volar angulation that is best seen on the lateral view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80762 \" href=\"UTD.htm?12/1/12319\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70381 \" href=\"UTD.htm?2/17/2320\">",
"     image 4",
"    </a>",
"    ). Avulsion fractures can occur at the base of the proximal phalanx and may involve the volar plate of the metacarpal-phalangeal (MCP) joint or collateral ligaments. Shaft fractures of the proximal phalanx are often oblique or spiral (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56508 \" href=\"UTD.htm?22/28/22991\">",
"     image 5",
"    </a>",
"    ). They may be stable if the periosteal sleeve remains intact (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83504 \" href=\"UTD.htm?24/18/24870\">",
"     image 6",
"    </a>",
"    ). Distal fractures of the proximal phalanx are less common (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82057 \" href=\"UTD.htm?30/14/30945\">",
"     image 7",
"    </a>",
"    ). Condylar fractures at the head of the proximal phalanx generally involve one condyle and are often unstable (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59144 \" href=\"UTD.htm?1/26/1455\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70897 \" href=\"UTD.htm?6/2/6191\">",
"     image 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hand or orthopedic surgeon should be consulted emergently for any open fracture and any fracture associated with a tendon or nerve injury.",
"   </p>",
"   <p>",
"    All intraarticular, unstable, rotated, shortened, or significantly angulated fractures should be referred to an orthopedic or hand surgeon. The majority of spiral and oblique fractures, condylar fractures, neck fractures, and large avulsion fractures are unstable and therefore warrant referral.",
"   </p>",
"   <p>",
"    Referral is necessary whenever a fracture cannot be reduced or the reduction cannot be maintained.",
"    <strong>",
"     NO",
"    </strong>",
"    degree of rotation is acceptable following a reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/4\">",
"     4",
"    </a>",
"    ]. Less than 10 degrees of angulation and less than 2 mm of shortening may be tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal phalanx fractures that require orthopedic referral should be placed in a radial or ulnar gutter splint, depending upon the finger involved, with the metacarpal-phalangeal (MCP) joint in 70 to 90 degrees of flexion and the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints in slight flexion (",
"    <a class=\"graphic graphic_picture graphicRef65376 \" href=\"UTD.htm?28/12/28879\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nondisplaced stable fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transverse, oblique, or avulsion fracture that is nondisplaced, not angulated, and appears stable can be treated initially by splinting and buddy taping the injured finger to an adjacent finger (",
"    <a class=\"graphic graphic_picture graphicRef79535 \" href=\"UTD.htm?21/8/21635\">",
"     picture 4",
"    </a>",
"    ). If the ring finger is involved, it should be buddy taped to the little finger. An ulnar or radial gutter or Burkhalter splint can be used for increased comfort and stability if needed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The Burkhalter splint is described in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Displaced or angulated fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angulated transverse fractures generally present with apex-volar angulation. This angulation results from the pull of the intrinsic hand muscles on the proximal fragment into flexion and a concomitant extension force from the extensor insertion acting on the distal fragment via the middle phalanx [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/5\">",
"     5",
"    </a>",
"    ]. Closed reduction of such fractures can produce satisfactory alignment. A digital block provides adequate anesthesia for the procedure.",
"   </p>",
"   <p>",
"    To perform a closed reduction, flex the MCP and PIP joints to 90 degrees. Flexion of the MCP joint to 90 degrees reduces the volar force exerted upon the proximal fragment by relaxing the interosseous muscles and tightening the stabilizing collateral ligaments. Flexion of the PIP joint allows for reduction of the distal fragment.",
"   </p>",
"   <p>",
"    After positioning the joints, use a three-point reduction technique to reduce the proximal fragment dorsally and the distal fragment volarly. The fragment ends should meet at the fracture line.",
"   </p>",
"   <p>",
"    Once the reduction is achieved, the PIP joint should be extended to avoid a flexion contracture, while the MCP joint remains in 70 to 90 degrees of flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The reduction is held in position by a radial or ulnar gutter splint (",
"    <a class=\"graphic graphic_picture graphicRef65376 \" href=\"UTD.htm?28/12/28879\">",
"     picture 3",
"    </a>",
"    ), with the fractured finger buddy taped to an adjacent finger.",
"   </p>",
"   <p>",
"    A Burkhalter splint can be used in place of a gutter splint if there is concern about joint stiffness arising from immobilization of the PIP joint. As an example, such concern may arise when treating the elderly or patients whose livelihood depends upon fine motor movement. In the Burkhalter, the wrist is placed in 30 degrees of extension with the MCP in 90 degrees of flexion (",
"    <a class=\"graphic graphic_picture graphicRef77846 \" href=\"UTD.htm?7/0/7183\">",
"     picture 5",
"    </a>",
"    ). A dorsal splint is placed from the forearm to the PIP joint. A volar splint is placed from the forearm to the proximal palmar crease. This provides immobilization of the MCP joint but allows PIP and DIP motion.",
"   </p>",
"   <p>",
"    Evidence supporting use of the Burkhalter splint is scant. In one observational study involving 45 patients with 48 displaced proximal phalanx fractures, only four patients treated with a dynamic splint similar to the Burkhalter showed signs of restricted joint motion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DEFINITIVE TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nondisplaced stable fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondisplaced fractures are reevaluated one week following the initial injury. Reassessment includes a careful physical and radiographic examination looking for evidence of displacement, shortening, angulation, or rotation. Once the fracture is stable, the splint can be removed and buddy taping to an adjacent finger used in its place to provide stability. Evaluations are repeated every one to two weeks until clinical healing occurs, generally within four to six weeks. Clinical healing is indicated by the absence of pain with palpation or motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Displaced or angulated fractures treated with reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displaced or angulated fractures that are successfully reduced should be reevaluated one week following reduction. Reassessment is especially important for oblique or angulated fractures managed non-operatively since loss of reduction is common. Reassessment includes a careful physical and radiographic examination looking for evidence of displacement, shortening, angulation, or rotation. Evaluations are repeated every one to two weeks while treatment continues with a gutter or Burkhalter splint. Clinical healing, indicated by the absence of pain with palpation or motion, generally occurs within three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/2\">",
"     2",
"    </a>",
"    ]. Splinting is discontinued at this time and protected mobilization instituted to avoid tendon contractures. Buddy taping is used to protect the finger for several additional weeks. Full radiographic healing may require up to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO WORK OR SPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nondisplaced proximal phalanx fractures may return to work and sport once pain is controlled provided that protective buddy taping is used. Displaced or angulated fractures require three to four weeks of protective splinting, during which time high risk activities should be avoided. Patients may then return to work and sport, but buddy taping should be used for an additional three to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the proximal phalanx can lead to disabling complications. Significant angulation, shortening, or rotation of the fracture can lead to finger malrotation (",
"    <a class=\"graphic graphic_picture graphicRef71612 \" href=\"UTD.htm?38/20/39232\">",
"     picture 2",
"    </a>",
"    ) and abnormal hand mechanics. A \"pseudo-claw\" deformity with loss of PIP extension and hyperextension of the MCP joint can develop with persistent volar angulation of the fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/6\">",
"     6",
"    </a>",
"    ]. Tendon contractures can occur with prolonged or inappropriate immobilization. Joint stiffness and loss of motion is more common in elderly patients and fractures associated with underlying tendon injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/2\">",
"     2",
"    </a>",
"    ]. Proximal phalanx fractures may result in mild joint stiffness after treatment. Rehabilitation can help to improve function following such injuries. Nonunion occurs in less than one percent of fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20037/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=see_link\">",
"       \"Patient information: Finger fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures of the proximal phalanx are caused by a direct blow, rotary force, or hyperextension of the phalanx. The injured hand should be examined for deformity, neurovascular compromise, focal tenderness, and tendon dysfunction. Some degree of angulation, shortening, or rotation may exist. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proximal phalanx fractures are often unstable and at high risk for angulation, rotation, and shortening. Radiographs should be carefully examined for such deformities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hand or orthopedic surgeon should be consulted emergently for any open fracture and any fracture associated with a tendon or nerve injury. All intraarticular, unstable, rotated, shortened, or significantly angulated fractures should be referred. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nondisplaced, stable proximal phalanx fractures are treated with immobilization using a splint and buddy taping or a splint alone. Angulated transverse fractures generally present with apex-volar angulation. Closed reduction of such fractures can produce satisfactory alignment. Displaced proximal phalanx fractures are treated with a gutter or Burkhalter splint until early healing has occurred (typically three to four weeks post-injury), and are then treated with buddy taping for an additional three to four weeks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20037/abstract/1\">",
"      Widgerow AD, Ladas CS. Anatomical attachments to the proximal phalangeal base--a case for stability. Scand J Plast Reconstr Surg Hand Surg 2001; 35:85.",
"     </a>",
"    </li>",
"    <li>",
"     Stern P. Fractures of the metacarpals and phalanges. In: Green's Operative Hand Surgery, 5th, Green DP, Pederson WC, Hotchkiss RN, Wolfe SW.  (Eds), Elsevier - Churchill Livingstone, Philadelphia 2005. p.277.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20037/abstract/3\">",
"      Schriger DL, Baraff L. Defining normal capillary refill: variation with age, sex, and temperature. Ann Emerg Med 1988; 17:932.",
"     </a>",
"    </li>",
"    <li>",
"     Eiff P, Hatch R, Calmbach W. Fracture Management for Primary Care, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20037/abstract/5\">",
"      Kozin SH, Thoder JJ, Lieberman G. Operative treatment of metacarpal and phalangeal shaft fractures. J Am Acad Orthop Surg 2000; 8:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20037/abstract/6\">",
"      Hardy MA. Principles of metacarpal and phalangeal fracture management: a review of rehabilitation concepts. J Orthop Sports Phys Ther 2004; 34:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20037/abstract/7\">",
"      Ebinger T, Erhard N, Kinzl L, Mentzel M. Dynamic treatment of displaced proximal phalangeal fractures. J Hand Surg Am 1999; 24:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20037/abstract/8\">",
"      Seno N, Hashizume H, Inoue H, et al. Fractures of the base of the middle phalanx of the finger. Classification, management and long-term results. J Bone Joint Surg Br 1997; 79:758.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 233 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20037=[""].join("\n");
var outline_f19_36_20037=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nondisplaced stable fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Displaced or angulated fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DEFINITIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nondisplaced stable fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Displaced or angulated fractures treated with reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECOMMENDATIONS FOR RETURN TO WORK OR SPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/233|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/48/14081\" title=\"diagnostic image 1\">",
"      Normal finger radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/49/25364\" title=\"diagnostic image 2\">",
"      X-ray angulated fracture of proximal phalanx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/1/12319\" title=\"diagnostic image 3\">",
"      Proximal phalanx transverse fracture lateral xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/17/2320\" title=\"diagnostic image 4\">",
"      Proximal phalanx transverse fracture AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/28/22991\" title=\"diagnostic image 5\">",
"      Proximal phalanx oblique fracture AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/18/24870\" title=\"diagnostic image 6\">",
"      X-ray incomplete stable fracture proximal phalanx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/14/30945\" title=\"diagnostic image 7\">",
"      Proximal phalanx distal fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/26/1455\" title=\"diagnostic image 8\">",
"      Proximal phalanx condylar fracture AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?6/2/6191\" title=\"diagnostic image 9\">",
"      Proximal phalanx condylar fracture lateral xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/233|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40528\" title=\"picture 1\">",
"      Examination metacarpal malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/20/39232\" title=\"picture 2\">",
"      Metacarpal fracture with malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28879\" title=\"picture 3\">",
"      Ulnar gutter splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/8/21635\" title=\"picture 4\">",
"      Finger buddy taping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/0/7183\" title=\"picture 5\">",
"      Burkhalter splint for metacarpal fractures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=related_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_36_20038="Sys masto BM stained for tryptase";
var content_f19_36_20038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow biopsy - systemic mastocytosis - tryptase staining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bone marrow shows multifocal dense infiltrates (arrow) of greater than 15 mast cells. The abnormal-appearing, spindle-shaped mast cells are typically located near thickened bony trabeculae. Tryptase staining is positive.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mariana C Castells, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20038=[""].join("\n");
var outline_f19_36_20038=null;
var title_f19_36_20039="Amlodipine and valsartan: Drug information";
var content_f19_36_20039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amlodipine and valsartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/39/14965?source=see_link\">",
"    see \"Amlodipine and valsartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5086103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exforge&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5086107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5086414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is individualized; combination product may be used as initial therapy or substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same antihypertensive class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial therapy: Amlodipine 5 mg and valsartan 160 mg once daily, dose may be titrated after 1-2 weeks of therapy. Maximum recommended doses: Amlodipine 10 mg daily; valsartan 320 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Add-on/replacement therapy: Amlodipine 5-10 mg and valsartan 160-320 mg once daily; dose may be titrated after 3-4 weeks of therapy. Maximum recommended doses: Amlodipine 10 mg daily; valsartan 320 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5086415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use of lower initial doses should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5086416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; safety and efficacy has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5086417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate impairment: Use with caution; amlodipine elimination prolonged and valsartan exposure doubled in patients with mild-to-moderate chronic disease compared to healthy volunteers.  No dosage adjustment for valsartan is necessary; however, a lower initial amlodipine dose may be required (possibly requiring use of the individual agents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, similar to patients with mild to moderate impairment, a lower initial amlodipine dose may be required (possibly requiring use of the individual agents); titrate slowly.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5086423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Exforge&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/160: Amlodipine 5 mg and valsartan 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     5/320 mg: Amlodipine 5 mg and valsartan 320 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/160: Amlodipine 10 mg and valsartan 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10/320: Amlodipine 10 mg and valsartan 320 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5086105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5086419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5086109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5086200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (5% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Anxiety (3%), somnolence (3%), dizziness (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (3% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (upper; 3%), diarrhea (3%), nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased (6% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (4%), upper respiratory tract infection (3%), cough (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &lt;1% (Limited to important or life-threatening): Exanthema, hypersensitivity, hypotension, orthostatic hypotension, postural dizziness, syncope, tinnitus, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Frequency not defined, but occurred at &ge;0.2% incidence (limited to important or life-threatening): Abdominal discomfort/distension, arthralgia, chest pain, colitis, constipation, depression, diabetes, dyspepsia, dyspnea, edema (including pitting), epistaxis, erectile dysfunction, erythema, fever, flushing, gastritis, gout, hematuria, hypercholesterolemia, hypoesthesia, LFTs increased, lymphadenopathy, muscle spasm, myalgia, nephrolithiasis, palpitation, paresthesia, pharyngitis, pollakiuria, pruritus, rash, sinus congestion, somnolence, tachycardia, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5086161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amlodipine, valsartan, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5086162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with valsartan use; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with amlodipine/valsartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; use caution during initiation of therapy, particularly in patients with heart failure, severe aortic stenosis, or in post-MI patients or those undergoing surgery or dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema; occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: Valsartan may be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; amlodipine and valsartan exposure increases with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use valsartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Exposure to amlodipine is increased in the elderly; consider use of a lower initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5086402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5086401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5086405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Decreases rate and extent of valsartan absorption by 50% and 40%, respectively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effects).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5086110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5087188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5086159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5086160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5086418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes which contain potassium. May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5552126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Exforge Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-160 mg (30): $144.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-320 mg (30): $183.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-160 mg (30): $163.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-320 mg (30): $207.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5086421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic electrolyte panels, renal and liver function, urinalysis; BP, heart rate, peripheral edema; in HF, serum potassium during dose escalation and periodically thereafter",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amval (CO, GT);",
"     </li>",
"     <li>",
"      Copalia (EE, PT, SE);",
"     </li>",
"     <li>",
"      Diovan/Amlibon (VE);",
"     </li>",
"     <li>",
"      Exforge (AR, AU, BE, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FR, GB, GR, HK, ID, IE, IL, KP, MY, NO, NZ, PE, PH, PT, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Imprida (CZ, EE, PT, SE);",
"     </li>",
"     <li>",
"      Simultan A (AR);",
"     </li>",
"     <li>",
"      Vartalan AM (CN);",
"     </li>",
"     <li>",
"      Varteral (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5086408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Amlodipine inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina. Amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Valsartan produces direct antagonism of the angiotensin II (AT2) receptors, unlike the ACE inhibitors. It displaces angiotensin II from the AT1 receptor and produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5086410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Glazer R, Karagiannis S, et al, &ldquo;Tolerability and Blood Pressure-Lowering Efficacy of the Combination of Amlodipine Plus Valsartan Compared With Lisinopril Plus Hydrochlorothiazide in Adult Patients with Stage 2 Hypertension,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2007, 29(2):279-89.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/36/20039/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8659 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20039=[""].join("\n");
var outline_f19_36_20039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708610\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086103\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086107\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086414\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086415\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086416\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086417\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086423\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086105\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086419\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086109\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086200\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086161\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086162\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086402\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086401\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086405\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086110\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5087188\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086159\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086160\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086418\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5552126\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086421\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539993\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086408\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086410\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/39/14965?source=related_link\">",
"      Amlodipine and valsartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_36_20040="Natural killer (NK) cell large granular lymphocyte leukemia";
var content_f19_36_20040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural killer (NK) cell large granular lymphocyte leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Thierry Lamy, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Thomas P Loughran, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20040/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/36/20040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large granular lymphocyte (LGL) leukemia is characterized by peripheral blood and marrow lymphocytic infiltration with clonal LGLs, splenomegaly, and cytopenias, most commonly neutropenia. LGL leukemia arises most frequently (85 percent) from a T cell lineage or, less commonly (15 percent), from a natural killer (NK) cell lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The etiology, clinical features, diagnosis, and treatment of natural killer (NK) cell LGL disorders will be discussed here. T cell LGL leukemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link\">",
"     \"Treatment of large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE LARGE GRANULAR LYMPHOCYTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large granular lymphocyte (LGL) is a morphologically distinct lymphoid subset comprising 10 to 15 percent of normal peripheral blood mononuclear cells (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). The absolute number of LGLs in the peripheral blood of normal subjects is 200 to",
"    <span class=\"nowrap\">",
"     400/microL.",
"    </span>",
"    LGLs arise from two major lineages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD3 positive, CD 57 positive, CD56 negative T cells, representing in vivo antigen-activated cytotoxic effector T cells",
"     </li>",
"     <li>",
"      CD3-, CD56+ natural killer (NK) cells. It had been postulated that such NK cells mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. It is now established that NK cells possess specific receptors for MHC class I molecules named \"killer-cell Ig-like inhibitory receptor\" (KIR) and \"killer-cell activating receptor\" (KAR). Interactions between these receptors and MHC class I molecules on target cells may inhibit or activate NK cell-mediated cytotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary benign (nonclonal) LGL expansions have been reported in the following clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral infections (eg, EBV, HBV, HCV, HIV, CMV), connective tissue disease, immune thrombocytopenia (ITP), non-Hodgkin lymphoma, various skin disorders, and the hemophagocytosis syndrome are the main non-malignant situations that have been associated with reactive T cell LGL expansion (ie, CD3+ cells with T cell receptor genes in germline configuration) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1,3-5\">",
"       1,3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The myelodysplastic syndrome and solid tumors are sometimes associated with increased numbers of circulating NK LGL cells [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      NK cell proliferative disorders have been found in atomic-bomb survivors presenting with neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Classification of LGL disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome characterized by the proliferation of LGLs associated with neutropenia was initially reported in 1977 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/7\">",
"     7",
"    </a>",
"    ]. Since then, several studies of LGL proliferative disorders have appeared [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1,3,8-10\">",
"     1,3,8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term LGL leukemia was proposed for this disorder based upon demonstration of invasion of bone marrow, spleen, and liver by LGLs and the first proof that such LGLs were clonally expanded [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/11\">",
"     11",
"    </a>",
"    ]. A subsequent French-American-British (FAB) classification recognized LGL leukemia as one of four subgroups of chronic T cell lymphoid leukemias and, in 1993, it was proposed that LGL leukemias could be classified into T cell and natural killer (NK) cell types, depending upon the cell lineage of the leukemic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1\">",
"     1",
"    </a>",
"    ]. The revised European-American classification of lymphoid neoplasms (REAL) categorized LGL leukemia as a distinct entity classified under peripheral T cell and NK cell neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008 World Health Organization classification of mature T and NK cell neoplasms continues to distinguish T cell LGL leukemia (T-LGL leukemia) from aggressive NK cell leukemia based on their unique molecular and clinical features. Furthermore, a new provisional entity of chronic lymphoproliferative disorder of NK cells (also known as chronic NK cell lymphocytosis) was created to distinguish it from much more aggressive NK cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, the natural killer (NK) cell is associated with a",
"    <span class=\"nowrap\">",
"     CD3-/CD56+",
"    </span>",
"    phenotype. About 15 percent of patients with LGL proliferation have this phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1\">",
"     1",
"    </a>",
"    ]. These patients can be subclassified into two categories: chronic NK cell lymphocytosis and NK cell LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHRONIC NK CELL LYMPHOCYTOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Etiology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections have been implicated in the pathogenesis of NK lymphocytosis. In a series of 18 patients from Italy, there was evidence for viral infection in 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/14\">",
"     14",
"    </a>",
"    ]. We did not find any evidence of Epstein-Barr virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/15\">",
"     15",
"    </a>",
"    ] and no evidence of human T cell lymphotropic virus",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    was detected in a French series of 27 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/16\">",
"     16",
"    </a>",
"    ]. However, sera from patients with chronic NK lymphocytosis react to an envelope protein of HTLV",
"    <span class=\"nowrap\">",
"     I/II.",
"    </span>",
"    Using an epitope mapping technique, seroreactivity was detected at the specific BA21 epitope of this transmembrane envelope protein [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/17\">",
"     17",
"    </a>",
"    ]. It has therefore been hypothesized that a cellular or retroviral protein having homology to the BA21 epitope may be important in the pathogenesis of this disorder. Similar findings have been noted in T cell LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether chronic NK lymphocytosis represents a benign disorder or a chronic phase of NK cell LGL leukemia. Follow-up studies in patients with chronic NK lymphocytosis occasionally demonstrate clonal progression via the presence of new chromosomal abnormalities during a transformation into a more acute NK cell LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We and others have found skewed NK receptor expression on NK cells in patients with the natural killer (NK) type of lymphoproliferative disease of granular lymphocytes, with an increased activating-to-inhibitory killer-cell Ig-like inhibitory receptor (KIR) ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/20\">",
"     20",
"    </a>",
"    ]. This altered ratio might induce inappropriate lysis or cytokine production and affect disease pathogenesis.",
"   </p>",
"   <p>",
"    We have also found evidence of constitutive activation of the",
"    <span class=\"nowrap\">",
"     Ras/MEK/ERK",
"    </span>",
"    pathway in 13 of 13 patients with NK cell lymphoproliferative disease of large granular lymphocytes (12 with chronic and 1 with aggressive disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/21\">",
"     21",
"    </a>",
"    ]. Exposure of these cells to inhibitors of MEK or Ras resulted in apoptosis of patient NK cells, suggesting the use of inhibitors of this pathway in the treatment of these disorders. Activating mutations in STAT 3 occur in approximately 30 percent of these patients, similar to that observed in the T cell form of LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/22\">",
"     22",
"    </a>",
"    ]. This observation suggests a unifying pathogenesis for these disorders.",
"   </p>",
"   <p>",
"    A Cancer Therapy Evaluation Program (CTEP) approved phase II trial of the farnesyltransferase inhibitor (Zarnestra) for both T cell and NK cell LGL leukemia enrolled eight patients on study. Objective responses in hematologic parameters were not observed; however, improvement in pulmonary hypertension was seen in one patient with chronic NK cell lymphocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of all patients with LGL expansion have chronic NK cell lymphocytosis. The clinical features are similar to those of CD3+ T cell LGL leukemia. The median age is 60 years with a male to female ratio of 3.2. It is a chronic disease with a median duration of five years; no deaths were reported in a series of 10 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/24\">",
"     24",
"    </a>",
"    ]. Affected patients do not have lymphadenopathy; splenomegaly and hepatomegaly are rare. Vasculitis, including acute glomerulonephritis, urticarial vasculitis, and cutaneous polyarteritis nodosa, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/24\">",
"     24",
"    </a>",
"    ]. Pure cell aplasia, aplastic anemia, and mild thrombocytopenia have also been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of neutropenia is less than in T cell LGL leukemia. The median absolute number of NK cells is 2.3 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    <span class=\"nowrap\">",
"     (2300/microL)",
"    </span>",
"    and the main phenotype is",
"    <span class=\"nowrap\">",
"     CD2+/CD3-/CD4-/CD8-/CD16+/CD",
"    </span>",
"    56+. CD57 is usually weakly expressed. Different antigens expressed on NK cells subsets belonging to the 58 Kd molecular family have been described. Using the monoclonal antibodies EB6 and GL183, it is possible to distinguish four subsets of normal NK cells. Most patients with NK cell lymphocytosis have a restricted NK phenotype, with the NK expansion representing one of these four subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic NK cell lymphocytosis is suspected in a patient with clinically indolent disease and persistent peripheral blood lymphocytosis, in whom LGLs are seen on examination of the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). The great majority show a CD3-, CD4-, CD8-, CD16+, CD56+, CD57- phenotype (",
"    <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since NK lymphocytosis is an indolent disease, therapy is usually not needed. For patients with severe neutropenia, we suggest treatment with agents similar to those used in T cell LGL leukemia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , cyclophosphamide alone, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience with other agents is limited. One patient with symptomatic chronic NK lymphocytosis responded to treatment with the anti-CD52 monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of large granular lymphocyte leukemia\", section on 'Initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NK CELL LGL LEUKEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with Epstein-Barr virus (EBV) has been implicated in more than 50 percent of the cases of NK LGL leukemia reported in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/26\">",
"     26",
"    </a>",
"    ]. In situ hybridization analyses have shown EBV RNA within the LGLs; EBV nuclear antigen 1 (EBNA1) and EBER-1 can be detected in leukemic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data suggest that EBV may be directly involved in LGL cell transformation, similar to that seen in EBV-associated B cell lymphoma following solid organ or hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of NK cell LGL leukemia is more aggressive than that of T cell LGL leukemia and chronic NK cell lymphocytosis (",
"    <a class=\"graphic graphic_table graphicRef54785 \" href=\"UTD.htm?6/21/6492\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients are younger, with a median age of 39 years. Initial presentation includes \"B\" symptoms (fever, night sweats, weight loss) and the presence of considerable, often massive, hepatosplenomegaly. Involvement of the gastrointestinal tract is present in many patients, and infiltration of LGLs into the cerebrospinal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/31\">",
"     31",
"    </a>",
"    ] and peritoneal fluids, with clinical ascites, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/32\">",
"     32",
"    </a>",
"    ]. Rheumatoid arthritis has not been observed in this type of LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia (100 percent) and thrombocytopenia are more frequent than in T cell LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, severe neutropenia is less common, being present in about 18 percent of patients with NK-LGL leukemia. Bone marrow infiltration is seen in the majority of the patients, occasionally with marrow fibrosis.",
"   </p>",
"   <p>",
"    Absolute LGL counts are higher than in T cell LGL leukemia, often exceeding 10,000",
"    <span class=\"nowrap\">",
"     LGLs/microL.",
"    </span>",
"    The usual phenotype is CD3-, TCRab-, TCRgd-, CD4-, CD8+, CD16+, CD56+ [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/34\">",
"     34",
"    </a>",
"    ]. CD57 is variably expressed.",
"   </p>",
"   <p>",
"    Unlike CD3+ T cell LGL, CD3- NK cell LGLs do not express the T cell receptor (TCR), and thus clonality cannot be demonstrated by showing rearrangement of TCR genes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/35\">",
"     35",
"    </a>",
"    ]. However, cases described in Asia have been associated with nonrandom clonal cytogenetic abnormalities, including duplication of 1q, rearrangement at 3q, loss of chromosomes Y, 13, or 10, and trisomy 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/19,35,36\">",
"     19,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cell large granular lymphocyte (LGL) leukemia is suspected in a patient with aggressive clinical disease, neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia along with persistent peripheral blood lymphocytosis, in whom LGLs are seen on examination of the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). The great majority of NK cell LGL leukemias show a CD3-, CD4-, CD8+, CD16+, CD56+ phenotype (",
"    <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of NK-LGL leukemia includes a number of uncommon lymphomatous and leukemic conditions (",
"    <a class=\"graphic graphic_table graphicRef66306 \" href=\"UTD.htm?33/16/34059\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/30,37,38\">",
"     30,37,38",
"    </a>",
"    ]. An approach has been suggested to establish the diagnosis of T cell or NK cell LGL leukemia (",
"    <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Extranodal NK/T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma is a heterogeneous disease: most of the cases have been described in Asia, involve the nasopharynx, and are related to infection with EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/12,39-41\">",
"     12,39-41",
"    </a>",
"    ]. These cases have been termed extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type, and are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma involving sites outside the nasal cavity or upper respiratory tract is a rare, aggressive variant, with most patients dying within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Blastic NK cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic cases without nasal involvement unrelated to EBV have been described in Asia as well as Europe and North America [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. These cases have been termed blastic NK cell lymphoma or precursor NK cell lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma;",
"    </span>",
"    they may represent a malignancy of plasmacytoid dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], although the precise lineage of this malignancy has not been resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phenotype is variable, but is usually",
"    <span class=\"nowrap\">",
"     CD3-/CD4+/CD56+",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/42,44,46,48-50\">",
"     42,44,46,48-50",
"    </a>",
"    ]. The cells display intermediate or large size with features of pleomorphic cell lymphoma. The diagnosis of blastic NK cell lymphoma should be made in the absence of commitment to the T cell or myeloid lineages, and thus blasts should be negative for CD3, CD33, and myeloperoxidase, and the T cell receptor should be germline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/46\">",
"     46",
"    </a>",
"    ]. Gene expression profiling has been able to separate these cases from cutaneous myelomonocytic leukemia and to demonstrate high expression of various plasmacytoid dendritic cell-related genes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Median overall survival is approximately 12 months, and is longer in those with localized disease, especially the skin, than in patients with involvement of multiple organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/52\">",
"     52",
"    </a>",
"    ]. Radiation therapy is associated with a high initial complete remission rate, although local, regional, and systemic failure rates are also high [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/53\">",
"     53",
"    </a>",
"    ]. While complete responses to combination chemotherapy were described in 18 of 23 patients in one series, relapse has been common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/44,54\">",
"     44,54",
"    </a>",
"    ]. Long-term survival has been described following allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/43,44,55-57\">",
"     43,44,55-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     NK like T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive lymphomas of LGLs have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/40\">",
"     40",
"    </a>",
"    ]. All the patients presented with \"B\" symptoms and marked hepatosplenomegaly. Bone marrow infiltration and peripheral blood involvement by large neoplastic lymphocytes with both a CD3+ and CD56+ phenotype are observed. These patients probably have an illness similar to, if not identical with, a previously described aggressive CD3+, CD56+ variant of LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/58\">",
"     58",
"    </a>",
"    ]. The prognosis is very poor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with NK cell LGL leukemia have a severe and refractory clinical course. In our review, 9 of 11 patients died within two months after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/1\">",
"     1",
"    </a>",
"    ]. Multiorgan failure associated with coagulopathy was the main cause of death. Combination chemotherapy has been ineffective, and long-term remission has been obtained only rarely. The MDR phenotype may be implicated in drug resistance in these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thus far, no treatment has been found to be effective for this disorder. Accordingly, we suggest that patients with this disorder be enrolled in a well designed experimental treatment program, if available.",
"   </p>",
"   <p>",
"    There are isolated reports of success following allogeneic hematopoietic cell transplantation, which we suggest be pursued in patients with a suitable donor who are able to tolerate this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20040/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18080700\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18079112\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The large granular lymphocyte (LGL) is a morphologically distinct lymphoid subset comprising 10 to 15 percent of normal peripheral blood mononuclear cells (",
"      <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"       picture 1",
"      </a>",
"      ). LGLs arise from a T cell or NK cell lineage. Increased levels of circulating LGLs can be benign (nonclonal, secondary to other disorders) or malignant (clonal). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The large granular lymphocyte'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The current classification of mature T and NK cell neoplasms distinguishes T cell LGL leukemia from aggressive NK cell leukemia based on their unique molecular and clinical features. Chronic NK cell lymphocytosis is a provisional entity distinguished from the much more aggressive NK cell leukemia. It is not clear whether chronic NK cell lymphocytosis represents a benign disorder or a chronic phase of NK cell LGL leukemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification of LGL disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18080461\">",
"    <span class=\"h2\">",
"     Chronic NK cell lymphocytosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic NK cell lymphocytosis is suspected in a patient with clinically indolent disease and persistent peripheral blood lymphocytosis, in whom LGLs are seen on examination of the peripheral blood smear (",
"      <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"       picture 1",
"      </a>",
"      ). The great majority show a CD3-, CD4-, CD8-, CD16+, CD56+, CD57- phenotype (",
"      <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features and prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among newly diagnosed patients with asymptomatic chronic NK cell lymphocytosis, we suggest close observation rather than immediate treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment is reserved for patients with symptoms due to neutropenia, anemia, or thrombocytopenia, and for patients with associated autoimmune conditions requiring therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no agreed upon standard treatment regimen for symptomatic chronic NK cell lymphocytosis, but there is general agreement that immunosuppressive therapy, such as that administered for T cell LGL leukemia, is reasonable. A choice among immunosuppressive treatments is primarily made based upon the clinical setting and physician experience. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=see_link&amp;anchor=H30#H30\">",
"       \"Treatment of large granular lymphocyte leukemia\", section on 'Initial treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18080469\">",
"    <span class=\"h2\">",
"     NK cell LGL leukemia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NK cell large granular lymphocyte (LGL) leukemia is suspected in a patient with aggressive clinical disease, neutropenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anemia along with persistent peripheral blood lymphocytosis, in whom LGLs are seen on examination of the peripheral blood smear (",
"      <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"       picture 1",
"      </a>",
"      ). The great majority of NK cell LGL leukemias show a CD3-, CD4-, CD8+, CD16+, CD56+ phenotype (",
"      <a class=\"graphic graphic_algorithm graphicRef80765 \" href=\"UTD.htm?20/42/21167\">",
"       algorithm 1",
"      </a>",
"      ). The differential diagnosis of NK-LGL leukemia includes a number of uncommon lymphomatous and leukemic conditions (",
"      <a class=\"graphic graphic_table graphicRef66306 \" href=\"UTD.htm?33/16/34059\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with NK cell LGL leukemia have a severe and refractory clinical course. Multiorgan failure associated with coagulopathy is the main cause of death. Combination chemotherapy has been ineffective, and long-term remission has been obtained only rarely. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thus far, no treatment has been found to be effective for NK cell LGL leukemia; although isolated reports suggest a benefit from allogeneic hematopoietic cell transplantation (HCT). For patients with NK cell LGL leukemia, we suggest allogeneic HCT, ideally performed within the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who are not candidates for this approach should be encouraged to enroll in a well-designed experimental treatment program, if available. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/1\">",
"      Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/2\">",
"      Lamy T, Loughran TP Jr. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/3\">",
"      Oshimi K. Granular lymphocyte proliferative disorders: report of 12 cases and review of the literature. Leukemia 1988; 2:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/4\">",
"      Okuno SH, Tefferi A, Hanson CA, et al. Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. Br J Haematol 1996; 93:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/5\">",
"      Imashuku S, Hibi S, Morinaga S, et al. Haemophagocytic lymphohistiocytosis in association with granular lymphocyte proliferative disorders in early childhood: characteristic bone marrow morphology. Br J Haematol 1997; 96:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/6\">",
"      Imamura N, Kimura A. Neutropenia among survivors of atomic bomb explosion. Lancet 2000; 355:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/7\">",
"      McKenna RW, Parkin J, Kersey JH, et al. Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics. Am J Med 1977; 62:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/8\">",
"      Dhodapkar MV, Li CY, Lust JA, et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994; 84:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/9\">",
"      Zambello R, Trentin L, Ciccone E, et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood 1993; 81:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/10\">",
"      Semenzato G, Pandolfi F, Chisesi T, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer 1987; 60:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/11\">",
"      Loughran TP Jr, Kadin ME, Starkebaum G, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985; 102:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/12\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/13\">",
"      Lim MS, de Leval L, Quintanilla-Martinez L. Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms. J Hematop 2009; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/14\">",
"      Zambello R, Loughran TP Jr, Trentin L, et al. Serologic and molecular evidence for a possible pathogenetic role of viral infection in CD3-negative natural killer-type lymphoproliferative disease of granular lymphocytes. Leukemia 1995; 9:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/15\">",
"      Loughran TP Jr, Zambello R, Ashley R, et al. Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood 1993; 81:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/16\">",
"      Fouchard N, Flageul B, Bagot M, et al. Lack of evidence of HTLV-I/II infection in T CD8 malignant or reactive lymphoproliferative disorders in France: a serological and/or molecular study of 169 cases. Leukemia 1995; 9:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/17\">",
"      Loughran TP Jr, Hadlock KG, Yang Q, et al. Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood 1997; 90:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/18\">",
"      Loughran TP Jr, Hadlock KG, Perzova R, et al. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol 1998; 101:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/19\">",
"      Ohno Y, Amakawa R, Fukuhara S, et al. Acute transformation of chronic large granular lymphocyte leukemia associated with additional chromosome abnormality. Cancer 1989; 64:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/20\">",
"      Epling-Burnette PK, Painter JS, Chaurasia P, et al. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 2004; 103:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/21\">",
"      Epling-Burnette PK, Bai F, Wei S, et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 2004; 23:9220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/22\">",
"      Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/23\">",
"      Epling-Burnette PK, Sokol L, Chen X, et al. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 2008; 112:4694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/24\">",
"      Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999; 106:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/25\">",
"      Chee CE, Warrington KJ, Tefferi A. Chronic natural killer-cell lymphocytosis successfully treated with alemtuzumab. Blood 2009; 114:3500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/26\">",
"      Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989; 84:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/27\">",
"      Hart DN, Baker BW, Inglis MJ, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood 1992; 79:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/28\">",
"      Kanegane H, Wado T, Nunogami K, et al. Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Br J Haematol 1996; 95:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/29\">",
"      Gelb AB, van de Rijn M, Regula DP Jr, et al. Epstein-Barr virus-associated natural killer-large granular lymphocyte leukemia. Hum Pathol 1994; 25:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/30\">",
"      Lamy T, Loughran TP. Large Granular Lymphocyte Leukemia. Cancer Control 1998; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/31\">",
"      Ohno T, Kanoh T, Arita Y, et al. Fulminant clonal expansion of large granular lymphocytes. Characterization of their morphology, phenotype, genotype, and function. Cancer 1988; 62:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/32\">",
"      Sheridan W, Winton EF, Chan WC, et al. Leukemia of non-T lineage natural killer cells. Blood 1988; 72:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/33\">",
"      Fernandez LA, Pope B, Lee C, Zayed E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood 1986; 67:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/34\">",
"      Morice WG, Kurtin PJ, Leibson PJ, et al. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br J Haematol 2003; 120:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/35\">",
"      Shimodaira S, Ishida F, Kobayashi H, et al. The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage. Br J Haematol 1995; 90:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/36\">",
"      Chou WC, Chiang IP, Tang JL, et al. Clonal disease of natural killer large granular lymphocytes in Taiwan. Br J Haematol 1998; 103:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/37\">",
"      Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 2003; 40:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/38\">",
"      Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003; 40:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/39\">",
"      Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/40\">",
"      Macon WR, Williams ME, Greer JP, et al. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 1996; 87:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/41\">",
"      Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89:4501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/42\">",
"      Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer 1995; 75:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/43\">",
"      Dr&eacute;nou B, Lamy T, Amiot L, et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997; 89:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/44\">",
"      Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002; 99:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/45\">",
"      Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 2007; 136:539.",
"     </a>",
"    </li>",
"    <li>",
"     Chan JK, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.214.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/47\">",
"      B&eacute;n&eacute; MC, Feuillard J, Jacob MC, Groupe d'Etude Immunologique des Leuc&eacute;mies. Plasmacytoid dendritic cells: from the plasmacytoid T-cell to type 2 dendritic cells CD4+CD56+ malignancies. Semin Hematol 2003; 40:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/48\">",
"      Mori KL, Egashira M, Oshimi K. Differentiation stage of natural killer cell-lineage lymphoproliferative disorders based on phenotypic analysis. Br J Haematol 2001; 115:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/49\">",
"      Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fran&ccedil;ais de Cytog&eacute;n&eacute;tique H&eacute;matologique. Blood 2002; 99:4154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/50\">",
"      Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/51\">",
"      Dijkman R, van Doorn R, Szuhai K, et al. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007; 109:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/52\">",
"      Suzuki R, Nakamura S, Suzumiya J, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005; 104:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/53\">",
"      Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004; 59:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/54\">",
"      Shapiro M, Wasik MA, Junkins-Hopkins JM, et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen. Am J Hematol 2003; 74:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/55\">",
"      Yamada O, Ichikawa M, Okamoto T, et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol 2001; 113:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/56\">",
"      Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res 1999; 23:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/57\">",
"      Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/58\">",
"      Gentile TC, Uner AH, Hutchison RE, et al. CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood 1994; 84:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20040/abstract/59\">",
"      Takami A, Nakao S, Yachie A, et al. Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21:1279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4538 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20040=[""].join("\n");
var outline_f19_36_20040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18079112\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE LARGE GRANULAR LYMPHOCYTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Classification of LGL disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHRONIC NK CELL LYMPHOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Etiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NK CELL LGL LEUKEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Extranodal NK/T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Blastic NK cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - NK like T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18080700\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18079112\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18080461\">",
"      Chronic NK cell lymphocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18080469\">",
"      NK cell LGL leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4538|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/42/21167\" title=\"algorithm 1\">",
"      Evaluation for LGL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4538|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/1/28\" title=\"picture 1\">",
"      Large granular lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/21/6492\" title=\"table 1\">",
"      Features of NK LGL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/16/34059\" title=\"table 2\">",
"      Differential diagnosis of T-LGL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_36_20041="Approach to the patient with aphasia";
var content_f19_36_20041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with aphasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20041/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20041/contributors\">",
"     David Glenn Clark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20041/contributors\">",
"     Mario F Mendez, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20041/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/36/20041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Language is a distinctive human facility for communication through symbols. Aphasia is the loss of ability to produce",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    understand language. This usually manifests as a difficulty speaking or understanding spoken language but reading and writing are also usually impacted. Aphasia can also impact the use of manual sign language and Braille.",
"   </p>",
"   <p>",
"    This topic reviews the clinical assessment of aphasia, the major aphasia syndromes, and an initial approach to diagnostic evaluation and management. Specific conditions that cause aphasia are discussed in detail separately (see appropriate topic reviews). Other aspects of the neurologic examination, as well as the prognosis and treatment of aphasia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23303?source=see_link\">",
"     \"The mental status examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3111?source=see_link\">",
"     \"Aphasia: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large, complex neurocognitive network, usually located in the left hemisphere, subserves the capacity for human language [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Language centers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The language network comprises areas of perisylvian cortex, including the classical language areas of Broca and Wernicke. While these are not anatomically discrete areas, important neural networks subserving critical language function have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Broca's area or Brodmann's area 44 in the posterior inferior frontal gyrus enervates adjacent motor neurons subserving the mouth and larynx, and controls the output of spoken language.",
"     </li>",
"     <li>",
"      Wernicke's area or Brodmann's area 22, comprising the posterior two-thirds of the superior temporal gyrus, receives information from the auditory cortex and accesses a network of cortical associations to assign word meanings.",
"     </li>",
"     <li>",
"      The angular gyrus in the inferior parietal lobule is adjacent to visual receptive areas and subserves the perception of written language, as well as other language processing functions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other regions of the cerebrum contribute importantly to normal language. These include the insula, which is integral to normal articulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/2\">",
"     2",
"    </a>",
"    ], several frontal and temporal lobe regions that support sentence-level processing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/3\">",
"     3",
"    </a>",
"    ], and vast regions of temporal, occipital, and parietal cortex that support knowledge of words and their meanings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is likely that subcortical nuclei make a contribution to normal language performance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], evidence from perfusion imaging indicates that aphasic syndromes associated with ischemic subcortical lesions are often accompanied by perfusion defects that involve cortical language regions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The fact that these subcortical aphasias have been associated with a better prognosis than cortical varieties may be explained by their tendency to resolve with restoration of cortical perfusion.",
"   </p>",
"   <p>",
"    Finally, there is increasing evidence that cerebellar lesions may result in linguistic deficits, including grammatical disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cerebral dominance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals are left hemisphere dominant for language function. Cerebral dominance is influenced by handedness; of the 90 to 95 percent of people who are right handed, more than 95 percent have left-sided language dominance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/15\">",
"     15",
"    </a>",
"    ]. A smaller proportion of left-handed individuals, variably estimated between 31 to 70 percent, have left-sided language dominance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with right-sided language dominance tend to have less severe and less enduring aphasia after right-sided brain injury, suggesting that language lateralization is incomplete in these individuals. The presence of bilateral representation of language function in certain individuals is further supported by functional neuroimaging studies, as well as in studies of WADA testing performed in patients prior to epilepsy surgery. Such studies indicate that language networks are not as strongly lateralized in women compared to men, and in left-handed versus right-handed individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/7,11,16,18,19\">",
"     7,11,16,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities of the left cerebral hemisphere that are present during development may result in atypical hemispheric dominance. A substantial left hemisphere injury in childhood (before the age of six years) is likely to be associated with a shift in at least some language functions to the right [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/20\">",
"     20",
"    </a>",
"    ]. Atypical language dominance is also noted to be more common in patients with temporal lobe epilepsy, particularly when the pathology is most prominent in the left side [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any insult or pathologic process that results in damage or dysfunction of the language network may cause aphasia. The most common etiology is ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/23\">",
"     23",
"    </a>",
"    ]. Other structural causes include hemorrhagic stroke; neoplasm; cerebral abscess, encephalitis or other central nervous system infections; and traumatic brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/24\">",
"     24",
"    </a>",
"    ]. Multiple sclerosis and acute disseminated encephalomyelitis are uncommon but reported causes of aphasia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Structural etiologies usually produce fixed deficits with either an acute or subacute presentation depending upon the tempo of the underlying disease.",
"   </p>",
"   <p>",
"    Transient episodes of aphasia may occur with transient cerebral ischemia (TIA), migraine, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The presence of aphasia during a TIA is one risk factor that identifies an individual at relatively high risk of stroke in the next few days and weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In seizures, aphasia may be either an ictal phenomenon (eg, brief speech arrest at onset of a complex partial or secondary generalized seizure) or a postictal manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=see_link\">",
"     \"Etiology and clinical manifestations of transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A progressive aphasia can be a manifestation of neurodegenerative disease. In children, certain forms of epilepsy (such as Landau-Kleffner syndrome and epilepsy with continuous spike-and-waves during slow-wave sleep) are associated with a progressive loss of previously attained language function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/36\">",
"     36",
"    </a>",
"    ]. The aphasia may be the presenting symptom in 40 percent of Landau-Kleffner cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H10#H10\">",
"     \"Epilepsy syndromes in children\", section on 'Landau-Kleffner syndrome'",
"    </a>",
"    .) Primary progressive aphasia and semantic dementia are syndromes that occur in older adults and most commonly represent frontotemporal degeneration, less commonly Alzheimer disease, Creutzfeldt Jacob disease, or another form of neurodegenerative dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Primary progressive aphasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphasias are classically subdivided based on observed vascular syndromes &mdash; cerebral infarction being the most common etiology of aphasia. These are categorized as fluent or nonfluent aphasias, and then are further subdivided according to observed deficits in content, repetition, naming, comprehension, reading, and writing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fluency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluency is usually assessed qualitatively by listening to the patient's spontaneous speech. Nonfluent speech has the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sparse output, with a decreased number of words per minute.",
"     </li>",
"     <li>",
"      Shortened phrases, typically five words or less.",
"     </li>",
"     <li>",
"      Agrammatism, characterized by the omission or substitution of function words (eg, prepositions, articles, conjunctions) or suffixes (eg, \"ed\" for past events). This type of speech pattern is the most specific feature of dysfluency and often referred to as \"telegraphic\".",
"     </li>",
"     <li>",
"      Effortfulness, with hesitations and a disruption of the normal melodic rhythm. Occasionally, patients with normal speech melody and little effort in spontaneous speech will exhibit word-finding pauses that make the assessment of fluency more difficult; however, these patients should be classified as fluent.",
"     </li>",
"     <li>",
"      A breakdown of speech praxis, the ability to coordinate the articulatory movements required for comprehensible speech [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/42\">",
"       42",
"      </a>",
"      ]. This may be tested by asking the patient to repeatedly pronounce the syllables,",
"      <span class=\"nowrap\">",
"       /pa/,",
"      </span>",
"      <span class=\"nowrap\">",
"       /ta/,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       /ka/",
"      </span>",
"      (individually) and then to link the three together into a sequence",
"      <span class=\"nowrap\">",
"       /pa-ta-ka/.",
"      </span>",
"      Another approach is to ask the patient to repeat the word 'catastrophe' or 'artillery' as many times as possible in five or ten seconds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best objective measure of fluency is to record the patient's speech, count the number of words or morphemes in a group of utterances, and take the mean. However, even this may vary considerably in a given patient depending on the emotional valence and complexity of the conversational topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Language errors during spontaneous or tested speech should be noted. Patients with Wernicke's aphasia, for example, make paraphasic errors and neologisms. &nbsp;Paraphasic errors are usually either whole word (semantic) substitutions, eg, \"chair\" for \"table,\" or phonemic (literal) substitutions, eg, \"cable\" for \"table.\" Neologisms are entirely new nonwords. Patients are often unaware of their paraphasic errors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Repetition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetition is tested by asking the patient to repeat phrases of increasing complexity. \"Serial speech,\" consisting of over-learned sequences (such as \"one, two, three\" or \"A, B, C\") is preserved in all but the most severe cases. This should be followed by short sentences using high-frequency words (\"She did it,\" and \"This is it\"), then longer utterances with less frequent words (\"They heard him speak on the radio last night\"), and finally, complex, low-frequency phrases (\"Hopping hippopotamus,\" \"Methodist Episcopal,\" \"No ifs, ands, or buts\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Naming",
"    </span>",
"    &nbsp;&mdash;&nbsp;When testing naming, patients are asked to give the names of real objects available to the examiner, such as \"key,\" \"buttonhole,\" \"eyebrow,\" and \"knuckles.\" Words used less frequently are more difficult for the aphasic patient to retrieve and constitute a more sensitive test for anomia. Photographs or line drawings may also be used to assess anomia. The retrieval of verbs is generally best tested by using pictures.",
"   </p>",
"   <p>",
"    In addition to confrontational naming, word retrieval and production may be tested by asking the patient to \"name by definition,\" ie, the examiner provides a definition of an object or action, and the patient provides the appropriate name.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comprehension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehension is evaluated by giving a sequence of commands, beginning with one-step, midline commands (\"Close your eyes,\" or \"Stick out your tongue\"), and progressing to multi-step commands and those involving the extremities (\"Show me two fingers,\" \"Close your eyes and point to the window,\" \"Stand up, turn around, clap two times, and sit down\").",
"   </p>",
"   <p>",
"    Commands that require a body part to cross the midline (eg, \"Touch your right ear with your left thumb\") are more complex than those that do not. Commands involving increasingly complex grammatical structures can also be used (eg, \"Touch the coin with the pencil\"; \"With the comb, touch the coin\"). More complex questions (eg, \"Does a stone sink in water?\" \"Do you put on your shoes before your socks?\") and those using complex grammatical structures such as passive voice or possessive (eg, \"Is my aunt's uncle a man or a woman?\" \"If a lion was killed by a tiger, which one is still alive?\") can elicit comprehension deficits in those who can follow simple commands.",
"   </p>",
"   <p>",
"    The Token test is a structured evaluation of auditory comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/43\">",
"     43",
"    </a>",
"    ]. A series of commands involving twenty tokens of different shapes, size, and color is presented in increasing complexity from \"touch the small red square\" to \"put the large green circle under the small yellow square, before you touch the white circle.\"",
"   </p>",
"   <p>",
"    Impaired comprehension may be due to failure of speech sound discrimination, word recognition, auditory working memory, or syntactic structure building. Word recognition can be tested by asking the patient to point to items that are plainly visible or accessible. \"Two-way\" naming deficits, in which the patient can neither name an item nor point to it on command (despite being able to repeat the name) represent abnormal word comprehension; this is a characteristic feature of semantic dementia, a form of frontotemporal lobar dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H6#H6\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Semantic dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are asked to read aloud from a newspaper or from a list of single words. There may be dissociations in the ability to read regularly spelled words, irregular words, or pronounceable nonwords. Reading comprehension may be tested with written commands (eg, \"Fold this paper in half and put it on the table\") or with a written word-picture matching test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Writing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is asked to write a sentence spontaneously. It may also be useful to dictate material to the patient, particularly for testing of regularly spelled words, irregular words, and pronounceable nonwords. The patient can also be asked to write names of objects or actions in response to pictures. Accuracy with written naming may be dissociated from spoken naming [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other language assessments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bedside examination is sufficient in most cases to assess aphasia. Validated scales such as the Boston diagnostic aphasia examination and Western aphasia battery are often used in clinical studies and as part of neuropsychologic test batteries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not specific for aphasia, verbal fluency tasks provide a means for rapid assessment of word knowledge and verbal executive function and are useful in the assessment of semantic memory in neurodegenerative disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\", section on 'Language'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link&amp;anchor=H6#H6\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\", section on 'Semantic dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other neurologic examination features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The language examination is best interpreted in the context of the entire neurologic examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A broad mental status examination that includes the assessment of level of consciousness, attention, memory, praxis, executive function, and visuospatial abilities is important to avoid mistaking aphasia for other conditions causing mental status changes and vice versa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23303?source=see_link\">",
"     \"The mental status examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of aphasia should be usually made only in the setting of an otherwise intact sensorium. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Conditions mistaken for aphasia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hearing should be specifically tested; if abnormal, this must be taken into account when interpreting the examination of comprehension and repetition.",
"   </p>",
"   <p>",
"    Dysarthria may be present and should be noted. In the setting of the examination, it is usually easy to distinguish dysarthria from aphasia; however, when obtaining historical information from patients and observers about a past episode of speech disturbance it can be surprisingly challenging. Asking them to mimic the speech disturbance can be helpful.",
"   </p>",
"   <p>",
"    The presence or absence of other neurologic deficits contributes to localization and underlying etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A right-sided visual field disturbance suggests a left hemisphere lesion of the optic tract, lateral geniculate nucleus, optic radiations, or posterior cortices. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37848?source=see_link\">",
"       \"Homonymous hemianopia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A right hemiparesis with spasticity, abnormal reflexes, and a Babinski sign is common in the setting of nonfluent aphasias. At times, weakness will be very subtle, consisting only of a facial weakness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a pronator drift.",
"     </li>",
"     <li>",
"      Cerebellar findings, such as dysmetria and dysdiadochokinesia, are not commonly caused by lesions that result in aphasia, but cases have been reported in which aphasia seemed to result from cerebellar damage.",
"     </li>",
"     <li>",
"      Hemianesthesia suggests a parietal lobe or thalamic lesion. Fluent aphasia is more commonly associated with sensory deficits. Sensory deficits from parietal lobe lesions may include failure of two-point discrimination, astereognosis, and agraphesthesia. These may be difficult to reliably test in the patient with aphasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     APHASIA SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the assessment of language as described above, it should be possible to classify the aphasia according to one of the classic language syndromes listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef72780 \" href=\"UTD.htm?23/44/24269\">",
"     table 1",
"    </a>",
"    ). The Wernicke-Lichtheim model (",
"    <a class=\"graphic graphic_figure graphicRef50662 \" href=\"UTD.htm?9/13/9438\">",
"     figure 1",
"    </a>",
"    ) provides a means for conceptualizing these aphasia syndromes.",
"   </p>",
"   <p>",
"    Although modern aphasiology is increasingly viewing the language faculty according to more complex models, the Wernicke-Lichtheim model and this classification scheme maintains clinical utility as these syndromes are at least to some degree associated with neuroanatomic localization, etiology, and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46\">",
"     46",
"    </a>",
"    ]. As an example, in one study of 325 patients with aphasia resulting from cerebral infarction, 95 percent of patients had MRI lesions that corresponded to their clinical syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/47\">",
"     47",
"    </a>",
"    ]. Limitations of this model include that it does not formally consider basic linguistic elements such as phonology (the sound pattern of language), morphology (the combination of language's smallest meaningful units), syntax (the structure of sentences), semantics (the relationship of language to meaning), and pragmatics (nuances of articulation and discourse).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Broca's aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically localized to lesions affecting the frontal lobe, Broca's aphasia is characterized by nonfluency with sparse output and agrammatism (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Fluency'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Repetition is also impaired. Comprehension is relatively spared but is usually not completely normal, particularly for grammatically complex speech. Writing is generally affected in proportion to speech. The association between Broca's aphasia and Broca's area is most consistently observed in acute rather than chronic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is often an associated right hemiparesis and oral apraxia reflecting injury to contiguous structures in the motor and supplementary motor areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Wernicke's aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wernicke's aphasia is a fluent aphasia with markedly impaired comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46\">",
"     46",
"    </a>",
"    ]. In its classic form, speech is voluminous, but meaningless, containing paraphasic errors and neologisms. This is often described as \"word salad\". The speech usually retains normal cadence and intonation. Comprehension and production of written language is similarly impaired. The patient appears unaware of the deficit.",
"   </p>",
"   <p>",
"    Associated with lesions in the posterior superior temporal gyrus (Wernicke's area), there is typically no motor deficit with this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46,49\">",
"     46,49",
"    </a>",
"    ]. However, a right superior visual field defect may be present",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Conduction aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction aphasia refers to a syndrome of fluent aphasia with impaired repetition, frequent paraphasic errors (usually phonemic) but relatively preserved comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients often try repeatedly to correct their errors. Written language may be similarly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome may be observed during recovery from a Wernicke aphasia and also with lesions in the supramarginal gyrus or deep parietal white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/35,47,50,51\">",
"     35,47,50,51",
"    </a>",
"    ]. There is often no other accompanying neurologic deficit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Global aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A global aphasia includes deficits in all language functions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients are often mute or produce only nonword utterances. They cannot follow commands, although they may respond to the intonation or expression of the speech.",
"   </p>",
"   <p>",
"    Because this syndrome is usually associated with extensive perisylvian injury affecting both Broca's and Wernicke's areas, patients generally have a right hemiparesis and often a right visual field deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, case reports of global aphasia without hemiparesis have been reported in the setting of encephalitis, selective lesions involving both Broca's and Wernicke's areas, and as a late manifestation of degenerative dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Transcortical motor aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characterized by a nonfluent speech output, with good comprehension and repetition, patients with this type of aphasia appear to have difficulty initiating speech, as well as completing a thought. Writing is disrupted proportionately. This can occur during recovery from a Broca's aphasia or as a primary deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome has been described in infarcts involving the anterior cerebral artery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the anterior-middle cerebral artery watershed that damage the supplementary motor area",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    connections to the frontal perisylvian speech area [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/46,47,55,56\">",
"     46,47,55,56",
"    </a>",
"    ]. It may also occur in patients recovering from a Broca's aphasia. When associated with lesions in the mesial frontal lobe, patients may demonstrate apathy and lateralized frontal release signs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/56\">",
"     56",
"    </a>",
"    ]. In contrast, when associated with damage in the supplementary motor area, patients appear to make a great effort to speak, and may also demonstrate right-sided long tract signs (weakness, hyperreflexia, Babinski sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Transcortical sensory aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a fluent aphasia with frequent paraphasic errors and impaired comprehension that appears similar to a Wernicke's aphasia. One difference is intact repetition that can take the form of echolalia. Patients can often read aloud (sometimes with errors), but without comprehension. Among other theories, this syndrome has been interpreted as representing a disconnection between phonological processing, which remains intact, and lexical-semantic decoding, which is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome has been produced by lesions adjacent to Wernicke's area in the temporal-occipital or parietal-occipital areas (eg, angular gyrus) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/47,58\">",
"     47,58",
"    </a>",
"    ]. This can be a watershed zone between middle and posterior cerebral artery territories. Consistent with this localization, patients generally have no motor deficits, but may have lateralized sensory or visual field deficits (inferior quadrantanopia or hemianopia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Transcortical mixed aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a transcortical mixed aphasia have all features of a global aphasia except that repetition is spared. They have little to no spontaneous verbal speech, but may repeat what has just been said [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/59\">",
"     59",
"    </a>",
"    ]. When given the start of a common phrase, they are sometimes able to repeat and then finish it on their own. Comprehension of written and spoken language is severely impaired.",
"   </p>",
"   <p>",
"    Produced by injury to the anterior and posterior watershed area or by multifocal cerebral emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/47,59,60\">",
"     47,59,60",
"    </a>",
"    ], there are often other neurologic deficits. Depending on the clinical setting, this syndrome can occur in the setting of bihemispheric watershed damage that produces bilateral spastic quadriparesis (\"man in a barrel\" syndrome)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visual field loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Anomic aphasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;While anomia is a common feature of most aphasia syndromes, an isolated deficit of anomia can also occur. Patients with anomic aphasia cannot name (or write) the word for a particular item. Often, they can state the meaning and retrieve words related to the one for which they are searching. Spontaneous speech is characterized by pauses, circumlocution (substitution of related words or phrases), and occasional paraphasic errors, but is otherwise fluent with intact repetition and sentence comprehension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/24,61\">",
"     24,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated lesions in different anatomic sites have been described, including the basal temporal lobe, anterior inferior temporal lobe, the temporo-parieto-occipital junction, and the inferior parietal lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/24,47,61\">",
"     24,47,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aphasia-related disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure word deafness, alexia without agraphia, and pure word mutism are not technically disturbances in language, but are related to aphasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Pure word deafness",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a rare syndrome. Patients can comprehend written but not spoken language [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Spontaneous speech is usually normal, sometimes with paraphasic errors. Repetition is often preserved. The general neurologic examination is normal. Pure word deafness is usually associated with restricted lesions in the superior temporal gyrus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Alexia without agraphia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with this syndrome can write, but not read. Their ability to understand and produce oral speech remains intact. Lesions producing this deficit are in the left occipital lobe and extend to the splenium of the corpus callosum (eg, left posterior cerebral artery occlusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The patient has a right visual field defect. Visual information reaches the left visual field but pathways that allow interpretation of written language from the left visual field are interrupted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pure word mutism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also known as aphemia, pure word mutism produces deficits in the production of oral speech with retention of auditory comprehension as well as the ability to write. Dysarthria and facial paresis usually accompany this syndrome. Lesions typically lie in or around Broca's area, involving the lowermost part of the precentral gyrus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     CONDITIONS MISTAKEN FOR APHASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions may either obscure or be mistaken for aphasia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient with metabolic encephalopathy or delirium may have difficulty naming and fail to follow commands. Paraphasic errors, while relatively uncommon, may occur in an agitated delirium. This condition may be recognized by fluctuating attention and level of consciousness, along with agitation, hallucinations,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asterixis. Other focal neurologic signs that can accompany fluent aphasia (eg, visual field deficits) are generally absent in patients with metabolic encephalopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"       \"Acute toxic-metabolic encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Akinetic mutism can result from lesions of the mesial frontal region. Patients demonstrate a paucity of speech output and poor response to commands that may suggest aphasia. Observation of bilaterally decreased motor responses, not restricted to speech, helps identify akinetic mutism [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. Hypophonia is often present in akinetic mutism, but not in aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/70\">",
"       70",
"      </a>",
"      ]. These patients may exhibit signs of catatonia (waxy flexibility). However, a nonfluent aphasia may also accompany frontal lobe lesions (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Broca's aphasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Transcortical motor aphasia'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients who are depressed may be reluctant to converse and be examined, and may therefore appear to have comprehension or naming difficulties. Flattened affect, poor eye contact, and other evidence of withdrawal are important to note in this regard. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .) Contributing to potential diagnostic confusion is the fact that many patients with chronic aphasia are depressed; clinicians should consider that both conditions may be contributing to the clinical picture [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/71-73\">",
"       71-73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3111?source=see_link\">",
"       \"Aphasia: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with schizophrenia may have abnormal speech content that can include neologisms, and can be difficult to distinguish from fluent aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/74-76\">",
"       74-76",
"      </a>",
"      ]. Listening carefully to the speech content can help distinguish the two. An underlying theme or preoccupation is often discernible in the disorganized speech of a schizophrenic patient, but not in the patient with aphasia. The jargon output of a fluent aphasia seems accidental rather than volitional, while the neologisms produced by schizophrenic patients often seem to be \"made up\" and inflected in a manner appropriate for their context [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. Semantic and phonemic paraphasic errors are common with aphasia but rarely occur in schizophrenic speech [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/74\">",
"       74",
"      </a>",
"      ]. While fluent aphasia is associated with aberrant production of grammatical affixes and function words (paragrammatism) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/23\">",
"       23",
"      </a>",
"      ], schizophrenic language is not associated with a morphological disturbance [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/77\">",
"       77",
"      </a>",
"      ]. Persistent patient examination can usually reveal intact verbal comprehension in the individual with schizophrenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"       \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dysarthria is usually easy to distinguish from aphasia in the setting of a fixed deficit; however, when obtaining historical information from patients and observers about an episode of speech disturbance it can be challenging. The term \"garbled speech\", for example, can be applied to either condition. Asking them to mimic the speech disturbance they experienced or witnessed can be helpful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with a newly identified aphasia should undergo a structural brain scan, usually magnetic resonance imaging (MRI). If the presentation is abrupt, suggesting an acute cerebrovascular event, or if there are other findings that suggest an intracranial mass lesion, the examination may be urgent. The presence of an ischemic stroke should trigger further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .) Other identified structural brain lesions will usually also warrant further testing.",
"   </p>",
"   <p>",
"    Episodes of transient aphasia should prompt investigation of possible seizures or transient cerebral ischemia. Electroencephalography (EEG)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebrovascular imaging may be helpful in such patients. Prolonged EEG monitoring may be required to detect active seizure activity in some patients with aphasic status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20041/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aphasia with an insidious onset and gradual progression, especially in middle-aged or elderly individuals, suggests neurodegenerative disease, primary progressive aphasia, but a slowly growing mass lesion should be excluded in these patients as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=see_link\">",
"       \"Patient information: Aphasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphasia is the loss of ability to produce",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    understand written",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spoken language.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left hemisphere language dominance is present in more than 95 percent of individuals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cerebral dominance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neural network subserving language function is increasingly recognized to be a large and complex system involving regions throughout the cerebral hemisphere and possibly the cerebellum as well. Important language centers lie in the perisylvian region of the dominant hemisphere. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Language centers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic stroke is the most common cause of aphasia; however any structural brain pathology and certain neurodegenerative conditions can also produce aphasia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aphasias are classified into specific syndromes according to observed deficits in fluency, content, repetition, naming, comprehension, reading, and writing (",
"      <a class=\"graphic graphic_table graphicRef72780 \" href=\"UTD.htm?23/44/24269\">",
"       table 1",
"      </a>",
"      ). These syndromes have been associated in many cases with a specific neuroanatomic localization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Aphasia syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aphasias may be confused clinically with delirium, as well as acute and chronic psychiatric conditions. However, a careful clinical examination can usually distinguish these. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Conditions mistaken for aphasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with aphasia should have a neuroimaging study. The acuity of the presentation dictates the urgency of the testing. Patients with episodic aphasia should be additionally evaluated for seizures and transient cerebral ischemia. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/1\">",
"      Mesulam MM. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol 1990; 28:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/2\">",
"      Dronkers NF. A new brain region for coordinating speech articulation. Nature 1996; 384:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/3\">",
"      Dronkers NF, Wilkins DP, Van Valin RD Jr, et al. Lesion analysis of the brain areas involved in language comprehension. Cognition 2004; 92:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/4\">",
"      Damasio H, Grabowski TJ, Tranel D, et al. A neural basis for lexical retrieval. Nature 1996; 380:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/5\">",
"      Tranel D, Damasio H, Damasio AR. A neural basis for the retrieval of conceptual knowledge. Neuropsychologia 1997; 35:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/6\">",
"      Blank SC, Scott SK, Murphy K, et al. Speech production: Wernicke, Broca and beyond. Brain 2002; 125:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/7\">",
"      Alexander MP, Naeser MA, Palumbo CL. Correlations of subcortical CT lesion sites and aphasia profiles. Brain 1987; 110 ( Pt 4):961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/8\">",
"      Crinion J, Turner R, Grogan A, et al. Language control in the bilingual brain. Science 2006; 312:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/9\">",
"      Hillis AE, Wityk RJ, Barker PB, et al. Subcortical aphasia and neglect in acute stroke: the role of cortical hypoperfusion. Brain 2002; 125:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/10\">",
"      de Boissezon X, D&eacute;monet JF, Puel M, et al. Subcortical aphasia: a longitudinal PET study. Stroke 2005; 36:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/11\">",
"      Marien P, Engelborghs S, Fabbro F, De Deyn PP. The lateralized linguistic cerebellum: a review and a new hypothesis. Brain Lang 2001; 79:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/12\">",
"      Mari&euml;n P, Saerens J, Nanhoe R, et al. Cerebellar induced aphasia: case report of cerebellar induced prefrontal aphasic language phenomena supported by SPECT findings. J Neurol Sci 1996; 144:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/13\">",
"      Karaci R, Ozt&uuml;rk S, Ozbakir S, Cansaran N. Evaluation of language functions in acute cerebellar vascular diseases. J Stroke Cerebrovasc Dis 2008; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/14\">",
"      Ackermann H, Mathiak K, Riecker A. The contribution of the cerebellum to speech production and speech perception: clinical and functional imaging data. Cerebellum 2007; 6:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/15\">",
"      Szaflarski JP, Binder JR, Possing ET, et al. Language lateralization in left-handed and ambidextrous people: fMRI data. Neurology 2002; 59:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/16\">",
"      Isaacs KL, Barr WB, Nelson PK, Devinsky O. Degree of handedness and cerebral dominance. Neurology 2006; 66:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/17\">",
"      Knecht S, Dr&auml;ger B, Deppe M, et al. Handedness and hemispheric language dominance in healthy humans. Brain 2000; 123 Pt 12:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/18\">",
"      Hagmann P, Cammoun L, Martuzzi R, et al. Hand preference and sex shape the architecture of language networks. Hum Brain Mapp 2006; 27:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/19\">",
"      Shaywitz BA, Shaywitz SE, Pugh KR, et al. Sex differences in the functional organization of the brain for language. Nature 1995; 373:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/20\">",
"      Rathore C, George A, Kesavadas C, et al. Extent of initial injury determines language lateralization in mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS). Epilepsia 2009; 50:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/21\">",
"      Gaillard WD, Berl MM, Duke ES, et al. fMRI language dominance and FDG-PET hypometabolism. Neurology 2011; 76:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/22\">",
"      Gaillard WD, Berl MM, Moore EN, et al. Atypical language in lesional and nonlesional complex partial epilepsy. Neurology 2007; 69:1761.",
"     </a>",
"    </li>",
"    <li>",
"     Goodglass, H. Understanding Aphasia. Academic Press, San Diego 1993. p.104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/24\">",
"      Okuda B, Kawabata K, Tachibana H, et al. Postencephalitic pure anomic aphasia: 2-year follow-up. J Neurol Sci 2001; 187:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/25\">",
"      Devere TR, Trotter JL, Cross AH. Acute aphasia in multiple sclerosis. Arch Neurol 2000; 57:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/26\">",
"      Little RD, Goldstein JL. Alexia without agraphia in a child with acute disseminated encephalomyelitis. Neurology 2006; 67:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/27\">",
"      Mao-Draayer Y, Panitch H. Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization. Mult Scler 2004; 10:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/28\">",
"      Eriksen MK, Thomsen LL, Olesen J. Implications of clinical subtypes of migraine with aura. Headache 2006; 46:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/29\">",
"      Vincent MB, Hadjikhani N. Migraine aura and related phenomena: beyond scotomata and scintillations. Cephalalgia 2007; 27:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/30\">",
"      Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/31\">",
"      Ois A, Gomis M, Rodr&iacute;guez-Campello A, et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 2008; 39:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/32\">",
"      Aladdin Y, Snyder TJ, Ahmed SN. Pearls &amp; Oy-sters: selective postictal aphasia: cerebral language organization in bilingual patients. Neurology 2008; 71:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/33\">",
"      Profitlich T, Hoppe C, Reuber M, et al. Ictal neuropsychological findings in focal nonconvulsive status epilepticus. Epilepsy Behav 2008; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/34\">",
"      Loddenkemper T, Kotagal P. Lateralizing signs during seizures in focal epilepsy. Epilepsy Behav 2005; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/35\">",
"      Quigg M, Geldmacher DS, Elias WJ. Conduction aphasia as a function of the dominant posterior perisylvian cortex. Report of two cases. J Neurosurg 2006; 104:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/36\">",
"      Pearl PL, Carrazana EJ, Holmes GL. The Landau-Kleffner Syndrome. Epilepsy Curr 2001; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/37\">",
"      Nieuwenhuis L, Nicolai J. The pathophysiological mechanisms of cognitive and behavioral disturbances in children with Landau-Kleffner syndrome or epilepsy with continuous spike-and-waves during slow-wave sleep. Seizure 2006; 15:249.",
"     </a>",
"    </li>",
"    <li>",
"     Mendez, MF, Cummings, JL. Alzheimer's disease. In: Dementia. A Clinical Approach, 3rd ed, Butterworth-Heinemann, Philadelphia 2003. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/39\">",
"      Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/40\">",
"      Josephs KA, Boeve BF, Duffy JR, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005; 11:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/41\">",
"      Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/42\">",
"      Ogar J, Slama H, Dronkers N, et al. Apraxia of speech: an overview. Neurocase 2005; 11:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/43\">",
"      DE RENZI E, VIGNOLO LA. The token test: A sensitive test to detect receptive disturbances in aphasics. Brain 1962; 85:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/44\">",
"      Hillis AE, Rapp BC, Caramazza A. When a rose is a rose in speech but a tulip in writing. Cortex 1999; 35:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/45\">",
"      Berthier ML. Poststroke aphasia : epidemiology, pathophysiology and treatment. Drugs Aging 2005; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/46\">",
"      Hillis AE. Aphasia: progress in the last quarter of a century. Neurology 2007; 69:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/47\">",
"      Yang ZH, Zhao XQ, Wang CX, et al. Neuroanatomic correlation of the post-stroke aphasias studied with imaging. Neurol Res 2008; 30:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/48\">",
"      Ochfeld E, Newhart M, Molitoris J, et al. Ischemia in broca area is associated with broca aphasia more reliably in acute than in chronic stroke. Stroke 2010; 41:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/49\">",
"      Kertesz A, Lau WK, Polk M. The structural determinants of recovery in Wernicke's aphasia. Brain Lang 1993; 44:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/50\">",
"      Balasubramanian V. Dysgraphia in two forms of conduction aphasia. Brain Cogn 2005; 57:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/51\">",
"      Catani M, Jones DK, ffytche DH. Perisylvian language networks of the human brain. Ann Neurol 2005; 57:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/52\">",
"      Bang OY, Heo KG, Kwak Y, et al. Global aphasia without hemiparesis: lesion analysis and its mechanism in 11 Korean patients. J Neurol Sci 2004; 217:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/53\">",
"      Hanlon RE, Lux WE, Dromerick AW. Global aphasia without hemiparesis: language profiles and lesion distribution. J Neurol Neurosurg Psychiatry 1999; 66:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/54\">",
"      Taubner RW, Raymer AM, Heilman KM. Frontal-opercular aphasia. Brain Lang 1999; 70:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/55\">",
"      Freedman M, Alexander MP, Naeser MA. Anatomic basis of transcortical motor aphasia. Neurology 1984; 34:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/56\">",
"      Kumral E, Bayulkem G, Evyapan D, Yunten N. Spectrum of anterior cerebral artery territory infarction: clinical and MRI findings. Eur J Neurol 2002; 9:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/57\">",
"      Boatman D, Gordon B, Hart J, et al. Transcortical sensory aphasia: revisited and revised. Brain 2000; 123 ( Pt 8):1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/58\">",
"      Alexander MP, Hiltbrunner B, Fischer RS. Distributed anatomy of transcortical sensory aphasia. Arch Neurol 1989; 46:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/59\">",
"      Maeshima S, Nakagawa M, Terada T, et al. Transcortical mixed aphasia from ischaemic infarcts in a non-right handed patient. J Neurol 1999; 246:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/60\">",
"      Maeshima S, Toshiro H, Sekiguchi E, et al. Transcortical mixed aphasia due to cerebral infarction in left inferior frontal lobe and temporo-parietal lobe. Neuroradiology 2002; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/61\">",
"      Takeda M, Tachibana H, Shibuya N, et al. Pure anomic aphasia caused by a subcortical hemorrhage in the left temporo-parieto-occipital lobe. Intern Med 1999; 38:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/62\">",
"      Wirkowski E, Echausse N, Overby C, et al. I can hear you yet cannot comprehend: a case of pure word deafness. J Emerg Med 2006; 30:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/63\">",
"      Stefanatos GA, Gershkoff A, Madigan S. On pure word deafness, temporal processing, and the left hemisphere. J Int Neuropsychol Soc 2005; 11:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/64\">",
"      Otsuki M, Soma Y, Sato M, et al. Slowly progressive pure word deafness. Eur Neurol 1998; 39:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/65\">",
"      Rheims S, Nighoghossian N, Hermier M, et al. Aphemia related to a premotor cortex infarction. Eur Neurol 2006; 55:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/66\">",
"      Mendez MF. Aphemia-like syndrome from a right supplementary motor area lesion. Clin Neurol Neurosurg 2004; 106:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/67\">",
"      Fox RJ, Kasner SE, Chatterjee A, Chalela JA. Aphemia: an isolated disorder of articulation. Clin Neurol Neurosurg 2001; 103:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/68\">",
"      Ackermann H, Ziegler W. [Akinetic mutism--a review of the literature]. Fortschr Neurol Psychiatr 1995; 63:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/69\">",
"      Cartlidge N. States related to or confused with coma. J Neurol Neurosurg Psychiatry 2001; 71 Suppl 1:i18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/70\">",
"      Nagaratnam N, Nagaratnam K, Ng K, Diu P. Akinetic mutism following stroke. J Clin Neurosci 2004; 11:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/71\">",
"      Medina J, Weintraub S. Depression in Primary Progressive Aphasia. J Geriatr Psychiatry Neurol 2007; 20:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/72\">",
"      Kauhanen ML, Korpelainen JT, Hiltunen P, et al. Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke. Cerebrovasc Dis 2000; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/73\">",
"      Thomas SA, Lincoln NB. Factors relating to depression after stroke. Br J Clin Psychol 2006; 45:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/74\">",
"      Gerson SN, Benson F, Frazier SH. Diagnosis: schizophrenia versus posterior aphasia. Am J Psychiatry 1977; 134:966.",
"     </a>",
"    </li>",
"    <li>",
"     Kuperberg, G, Caplan, D. Language dysfunction in schizophrenia. In: Neuropsychiatry, 2nd ed, Schiffer, RB, Rao, SM, Fogel, BS (Eds), Lippincott, Williams and Wilkins, Philadelphia 2003. p.444.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/76\">",
"      Sambunaris A, Hyde TM. Stroke-related aphasias mistaken for psychotic speech: two case reports. J Geriatr Psychiatry Neurol 1994; 7:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/77\">",
"      Covington MA, He C, Brown C, et al. Schizophrenia and the structure of language: the linguist's view. Schizophr Res 2005; 77:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/78\">",
"      Hillis AE, Boatman D, Hart J, Gordon B. Making sense out of jargon: a neurolinguistic and computational account of jargon aphasia. Neurology 1999; 53:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20041/abstract/79\">",
"      Ericson EJ, Gerard EE, Macken MP, Schuele SU. Aphasic status epilepticus: electroclinical correlation. Epilepsia 2011; 52:1452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5106 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20041=[""].join("\n");
var outline_f19_36_20041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Language centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cerebral dominance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fluency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Repetition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Naming",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comprehension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Writing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other language assessments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other neurologic examination features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      APHASIA SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Broca's aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Wernicke's aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Conduction aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Global aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Transcortical motor aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Transcortical sensory aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Transcortical mixed aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Anomic aphasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aphasia-related disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Pure word deafness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Alexia without agraphia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pure word mutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CONDITIONS MISTAKEN FOR APHASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5106|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/13/9438\" title=\"figure 1\">",
"      Wernicke-Lichtheim model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5106|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/44/24269\" title=\"table 1\">",
"      Aphasia syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3111?source=related_link\">",
"      Aphasia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37848?source=related_link\">",
"      Homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/61/30674?source=related_link\">",
"      Patient information: Aphasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23303?source=related_link\">",
"      The mental status examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_36_20042="AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology";
var content_f19_36_20042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Lawrence D Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Wei Ai, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/36/20042/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/36/20042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection results in impaired cellular immunity, a condition known to predispose persons to develop neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As the lifespan of HIV-infected patients has increased, malignancies have become a known cause of morbidity and mortality in this population. Before the advent of highly active antiretroviral therapy (HAART), malignancies accounted for about 10 percent of HIV-related deaths. Since the routine implementation of HAART therapy, a cancer diagnosis is made in over 40 percent of HIV-infected patients during the course of the HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/5\">",
"     5",
"    </a>",
"    ], and over 28 percent of HIV-related deaths are attributable to malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three AIDS-defining malignancies: Kaposi's sarcoma, non-Hodgkin lymphoma (NHL) of high-grade pathologic type and of B cell or unknown immunologic phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/8\">",
"     8",
"    </a>",
"    ], and invasive cervical carcinoma. In addition, non-AIDS-defining malignancies contribute to mortality in HIV-infected persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, and pathobiology of AIDS-related non-Hodgkin lymphomas will be reviewed here. Issues related to Hodgkin lymphoma in the setting of HIV and the diagnosis and treatment of NHL in this population are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link&amp;anchor=H10#H10\">",
"     \"AIDS-related lymphomas: Primary central nervous system lymphoma\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link&amp;anchor=H17#H17\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506291#H1560506291\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-five to 40 percent of HIV-positive patients will develop a malignancy, with approximately 10 percent developing non-Hodgkin lymphoma (NHL) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/1,3,5,7,9-17\">",
"     1,3,5,7,9-17",
"    </a>",
"    ]. As an example, a series of 1073 HIV positive patients reported a total cancer incidence of 4 percent per year; the rate of NHL was 1.2 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/12\">",
"     12",
"    </a>",
"    ]. Although the rate of lymphoma in the HIV-infected population prior to the introduction of effective antiviral therapy appeared to be higher in non-Blacks than Blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/12,18\">",
"     12,18",
"    </a>",
"    ], this has not been borne out in more recent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/19\">",
"     19",
"    </a>",
"    ] These lymphomas appear to be more common in males than in females, regardless of antiretroviral use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with non-HIV-infected patients, patients who are seropositive for HIV have a substantially increased risk of developing lymphoma. After the widespread implementation of highly active antiretroviral therapy (HAART), the risk of NHL decreased initially and has remained stable since [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This decline in incidence appears to reflect improvements in CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis which included data on 444,172 patients from seven cancer registries demonstrated a risk of lymphoma development in the HIV positive population between 23 and 353-fold relative to the non-immunocompromised population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/25\">",
"     25",
"    </a>",
"    ]. Although these studies predominantly included persons who were not receiving highly active antiretroviral therapy (HAART), they did include significant numbers of patients who were receiving HAART, thereby potentially lowering the incidence. One analysis of 2566 HIV patients from an urban HIV clinic in which 26 percent of patients were receiving HAART demonstrated that the ratios of observed to expected new cases of lymphoma (standard incidence ratios) were 31 for systemic diffuse large B cell Lymphoma, 2100 for central nervous system lymphoma and 26 for Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Specific NHL subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS-related non-Hodgkin lymphoma (NHL) can be divided into three general categories based on location:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic NHL",
"     </li>",
"     <li>",
"      Primary central nervous system (CNS) lymphoma",
"     </li>",
"     <li>",
"      Primary effusion (or body cavity) lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic NHL accounts for the great majority of AIDS-related lymphomas, while primary CNS lymphoma accounts for about 15 percent, and primary effusion lymphoma for less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Systemic NHL can be further divided into common subtypes described in the World Health Organization (WHO) classification system (",
"    <a class=\"graphic graphic_table graphicRef79517 \" href=\"UTD.htm?24/49/25371\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common systemic NHL subtypes seen in HIV-positive persons are: [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27-30,32\">",
"     27-30,32",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Burkitt lymphoma (approximately 25 percent)",
"     </li>",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL, approximately 75 percent)",
"     </li>",
"     <li>",
"      Plasmablastic lymphoma (less than 5 percent)",
"     </li>",
"     <li>",
"      T cell lymphoma (1 to 3 percent)",
"     </li>",
"     <li>",
"      Indolent B cell lymphoma (less than 10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WHO classification does not order lymphoid neoplasm according to their aggressiveness, in part due to recognition that the natural history of these tumors shows significant patient-to-patient variability. However, some studies have separated histologic subtypes into three general categories (highly aggressive, aggressive, and indolent) according to the usual clinical behavior of each of the lymphoid neoplasms (",
"    <a class=\"graphic graphic_table graphicRef59978 \" href=\"UTD.htm?41/26/42412\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27,33-37\">",
"     27,33-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 70 to 90 percent of AIDS-related lymphomas are highly aggressive and are almost exclusively the immunoblastic variant of DLBCL and Burkitt lymphoma. Compared with the general population, the relative risk for highly aggressive lymphomas is increased more than 400-fold overall [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/38\">",
"       38",
"      </a>",
"      ], and 650-fold and 260-fold for DLBCL and Burkitt lymphoma, respectively among patients with HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link&amp;anchor=H8#H8\">",
"       \"Classification of the hematopoietic neoplasms\", section on 'Lymphoid neoplasms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The aggressive lymphomas, predominately other variants of DLBCL, comprise about 20 percent of AIDS-related lymphomas. Compared with the general population, the relative risk is increased more than 110-fold for aggressive lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27,38\">",
"       27,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      T cell lymphomas are uncommon in HIV disease. However, linkage of AIDS and Cancer registry data indicates an approximately 15-fold increase in these lymphomas in the HIV-positive population compared with the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/39\">",
"       39",
"      </a>",
"      ]. They represented 2.6 percent of all HIV-associated NHL diagnosed at a large urban medical center between 1982 and 2001 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/36\">",
"       36",
"      </a>",
"      ]. Multiple pathologic subtypes were seen. There are no recent epidemiologic data indicating the effect of HAART on the incidence of this group of lymphomas. They do not constitute an AIDS-defining malignancy.",
"     </li>",
"     <li>",
"      The indolent lymphomas are also uncommon, comprising less than 10 percent of AIDS-related lymphomas. They do not constitute an AIDS-defining malignancy. Compared with the general population, the relative risk is increased more 15-fold for indolent lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27,38\">",
"       27,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While many NHL subtypes are also seen in patients without immunocompromise, primary effusion lymphoma and plasmablastic lymphoma occur predominantly in immunocompromised patients, particularly those infected with HIV.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasmablastic lymphoma is estimated to account for about 2.6 percent of all HIV-related lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/40\">",
"       40",
"      </a>",
"      ], although the true incidence is not known.",
"     </li>",
"     <li>",
"      Primary effusion lymphoma is one of the least common of the AIDS-related lymphomas, accounting for less than 5 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link&amp;anchor=H2#H2\">",
"       \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with HIV, the incidence of primary central nervous system (PCNSL) lymphoma is 2 to 6 percent, but has been as high as 10 percent in an autopsy series in the pre-HAART era [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. This incidence is at least 1000 times higher than that of the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/41\">",
"       41",
"      </a>",
"      ]. PCNSL accounts for up to 15 percent of NHLs in HIV-infected patients compared with 1 percent of NHLs in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/27\">",
"       27",
"      </a>",
"      ]. There has been a clear decrease in the incidence of AIDS-related PCNSLs since the advent of HAART [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=see_link\">",
"       \"AIDS-related lymphomas: Primary central nervous system lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for AIDS-related lymphoma include both HIV-specific risk factors, such as the CD4 count and HIV viral load, and more general risk factors known to increase the risk of NHL in patients without HIV. The latter group of risk factors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Patient history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of developing NHL in the setting of HIV increases directly with the level of immune system dysfunction. The incidence, pathology, clinical presentation and course of AIDS-related lymphomas do not seem to be related to the risk factor for the HIV infection itself [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/15,34\">",
"     15,34",
"    </a>",
"    ]. Epstein-Barr virus (EBV) coinfection is a risk factor for and involved in the pathogenesis of subtypes of NHL. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'EBV coinfection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CD4 count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphomas (NHLs) are primarily encountered in patients with more advanced HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/14,45\">",
"     14,45",
"    </a>",
"    ], and a CD4 count that is usually below",
"    <span class=\"nowrap\">",
"     100/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/33,46,47\">",
"     33,46,47",
"    </a>",
"    ]. A history of a low CD4 count nadir may also be a significant risk factor for the development of NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/48\">",
"     48",
"    </a>",
"    ]. Retrospective and prospective studies have demonstrated an association between a lower most recent CD4 count and a higher risk of systemic NHL in patients who had or had not received prior HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/19,47,49\">",
"     19,47,49",
"    </a>",
"    ]. In comparison, an association between the nadir CD4 count and NHL development was not as strong [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a French prospective cohort study involving 52,278 HIV-infected patients, persons with CD4 counts less than 50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      were approximately 15-fold more likely to develop NHL when compared with those having CD4 count over 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/49\">",
"       49",
"      </a>",
"      ]. The risk ratio for NHL development gradually declined with increasing CD4 count such that patients with a CD4 count of 350 to 499",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      were approximately two times as likely to develop NHL than someone with a CD4 count over 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Matching AIDS and Cancer Registry data were compared for 325,516 persons with AIDS-related malignancies to look for associations between CD4 count and cancer incidence [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/24\">",
"       24",
"      </a>",
"      ]. For each",
"      <span class=\"nowrap\">",
"       50-cell/microL",
"      </span>",
"      decline in CD4 lymphocyte count, increased risks were identified for primary central nervous system (CNS) lymphoma and for non-CNS diffuse large B cell lymphoma, but not for systemic Burkitt lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/32\">",
"       32",
"      </a>",
"      ]. The effect of CD4 count was observed regardless of HAART use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HIV-related Burkitt lymphoma frequently develops in relatively younger patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when the CD-4 count is relatively high, typically over 200",
"    <span class=\"nowrap\">",
"     cell/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/32,35,50,51\">",
"     32,35,50,51",
"    </a>",
"    ]. Primary CNS lymphoma requires a more severe degree of immunosuppression than most other AIDS-related complications, as the CD4 counts in affected patients are generally less than",
"    <span class=\"nowrap\">",
"     50/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HIV viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high HIV viral load is also a risk factor for NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/11,54\">",
"     11,54",
"    </a>",
"    ]. The risk of NHL rises significantly for those with plasma HIV RNA levels &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/ml",
"    </span>",
"    compared with those with controlled viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/49\">",
"     49",
"    </a>",
"    ]. Two large cohort studies have demonstrated an increased risk for NHL in individuals with extended periods of uncontrolled HIV viremia while receiving antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/47,55\">",
"     47,55",
"    </a>",
"    ]. This effect was most pronounced for Burkitt lymphoma and was not observed for primary CNS lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/55\">",
"     55",
"    </a>",
"    ]. About 75 percent of these lymphomas develop in individuals with poorly-controlled HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/56\">",
"     56",
"    </a>",
"    ]; one-quarter, however, develop even when the HIV viral load is undetectable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although variable according to histologic subtype, the overall incidence of NHL has declined with the widespread use of highly active antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/22,56\">",
"     22,56",
"    </a>",
"    ]. Nevertheless, the incidence of NHL in HIV seropositive patients remains above that of the non-HIV-infected population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, while the incidence of AIDS-defining cancers decreased in the HAART era, the incidence of certain types of non-AIDS defining cancers, such as anal, lung, liver, and prostate cancers, as well as Hodgkin lymphoma, has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/48,58,59\">",
"     48,58,59",
"    </a>",
"    ], most likely reflecting aging and prolonged survival of HIV-infected individuals in the HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Swiss HIV Cohort Study, which included 12,959 HIV seropositive patients, the incidence of NHL peaked at 13.6 per 100,000 person years in 1993 to 1995, and then declined to 1.8 in 2002 to 2006. HAART use was associated with a decline in incidence and this decline was greatest for those with primary CNS lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/21\">",
"       21",
"      </a>",
"      ]. After the initiation of HAART, the risk of NHL was halved by five months and continued to fall. The reduction in NHL risk persisted unchanged up to nine years after HAART initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/62\">",
"       62",
"      </a>",
"      ]. In patients receiving HAART there was a marked decline in the number of lymphoma cases and a shift toward increased CD4 count at diagnosis (",
"      <a class=\"graphic graphic_figure graphicRef59898 \" href=\"UTD.htm?2/56/2958\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similarly, an Italian AIDS and Cancer registry study demonstrated an 86 percent fall in the incidence of primary CNS lymphoma and a 79 percent reduction in the incidence of systemic NHL from the period 1986 to 1996 and 1997 to 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United States, the estimated number of AIDS-defining cancers decreased by greater than threefold from the four years prior to HAART introduction (1991 to 1995) to a four year span after HAART was employed (2001 to 2005) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although decreasing HIV viral load may be at least partly responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/47\">",
"     47",
"    </a>",
"    ], the most likely effect of HAART is a reduction in the proportion of patients with the low CD4 levels or histories of low CD4 count nadirs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/48\">",
"     48",
"    </a>",
"    ], the group most likely to develop high grade NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/48,64,65\">",
"     48,64,65",
"    </a>",
"    ]. Burkitt lymphomas, which can occur in those with relatively high CD4 counts, are being encountered with increasing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/66\">",
"     66",
"    </a>",
"    ]. The presenting clinical features of AIDS-related lymphomas are the same in the pre- and post-HAART eras [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link&amp;anchor=H1560489307#H1560489307\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy for the underlying HIV infection that includes non-nucleoside reverse-transcriptase inhibitors (NNRTIs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    protease inhibitors (PIs) may decrease the risk of developing a lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/68\">",
"     68",
"    </a>",
"    ]. The magnitude of this curtailment in risk seems to be equivalent between PIs and NNRTIs, while the protective effect for nucleoside analogues alone is inferior [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     B cell abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of HIV infection is progressive loss of CD4 lymphocytes, but B cell dysfunction is also present as evidenced by abnormally low levels of antibodies to specific pathogens and a poor immune response to vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/69\">",
"     69",
"    </a>",
"    ]. Paradoxically, total serum levels of immunoglobulins are elevated, reflecting nonspecific polyclonal B cell activation.",
"   </p>",
"   <p>",
"    Markers of B cell activation (such as total serum immunoglobulins, serum free light chains, and serum soluble CD30) may be predictive for the development of NHL in HIV-infected individuals, particularly in those with relatively preserved CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/22,47,48,50-53,56,57,64,65,67-70\">",
"     22,47,48,50-53,56,57,64,65,67-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients who have the CCR5-32 deletion tend to have a more favorable prognosis with respect to the HIV infection; these patients also are less likely, by a factor of threefold, to develop an AIDS-related lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. This protection, however, does not seem to apply to other AIDS-related neoplasms. It has been speculated that the reduced activity of CCR5 in those patients with the 32 base pair deletion results in a decrease in the mitogenic response to RANTES and, therefore, a lower risk of malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other genetic mutations may adversely affect the risk of developing an AIDS-related lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/72\">",
"     72",
"    </a>",
"    ]. One group has shown that a polymorphism in the gene that encodes for the CXCR-4 chemokine receptor was associated with a two- to fourfold increase in the risk of developing an AIDS-related non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the HIV-seronegative population, there is an elevated risk of lymphoproliferative disorders in those with a family history of such, particularly in a first-degree relative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/74\">",
"     74",
"    </a>",
"    ]. This risk is presumed to apply to the HIV-positive population as well, although not yet demonstrated with clinical data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of NHL in the setting of HIV infection is poorly understood, but immune deregulation leading to loss of control of viruses, such as Epstein Barr virus (EBV) is thought to play an important role.",
"   </p>",
"   <p>",
"    AIDS-related NHLs are most commonly derived from B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/75\">",
"     75",
"    </a>",
"    ]. There is an unregulated expansion of cells that are arrested in development and unable to undergo terminal differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/54\">",
"     54",
"    </a>",
"    ]. Genetic alterations may be involved, not only in the pathogenesis of AIDS-related lymphomas, but also in determining the histology of the resulting clonal proliferation(s).",
"   </p>",
"   <p>",
"    Further description of the molecular pathogenesis of DLBCL and BL in immunocompetent hosts is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link\">",
"     \"Pathobiology of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Immune dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of AIDS-related lymphoid neoplasms is at least partially related to the progressive impairment of dendritic cell function and the resulting functional disorganization of lymph nodes that occurs with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. This progression likely results from the increased production of cytokines (eg, interleukin-6 and interleukin-10) from the damaged dendritic cells that are known to drive lymphoid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another factor that plays a role in the genesis, progression, and spread of AIDS-related lymphomas is the enhanced adhesion of neoplastic lymphocytes to endothelial cells that results from the infection of the latter by HIV itself. This brings the neoplastic cells into close proximity to growth factors produced by the endothelial cells and accelerates extravasation of the malignant cells into the tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV does not infect the neoplastic cells of AIDS-related lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/81\">",
"     81",
"    </a>",
"    ]. One study, however, has indicated that the Tat protein of HIV may be taken up by B lymphocytes, leading to deregulation of the oncosuppressor protein products of the",
"    <span class=\"nowrap\">",
"     pRb2/p130",
"    </span>",
"    gene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/82\">",
"     82",
"    </a>",
"    ]. The Tat protein may also be active in the pathogenesis of tumors in the HIV-infected population by augmenting the angiogenic activities of bFGF and VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     EBV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many AIDS-related systemic lymphomas demonstrate direct infection of the malignant cells with Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. The high frequency of EBV-infected B cells in patients with AIDS, independent of the development of lymphoma, may be due in part to a defect in T cell immunity to EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. The risk of developing an AIDS-related lymphoma correlates with the decrease in EBV-specific cytotoxic lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/87,91,92\">",
"     87,91,92",
"    </a>",
"    ]. Unlike the situation in the post organ transplant setting, in the HIV-seropositive population the risk of lymphoma does not correlate well with the EBV viral load in peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found that the numbers of EBV-specific CD8 cells did not fall, but rather production of interferon-gamma decreased following EBV-peptide stimulation in association with an increase in EBV viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that immunosuppression and EBV infection favor the expansion of B cell clones, thereby allowing clones of cells that have undergone alterations in oncogenes or tumor suppressor genes to proliferate. Some of these genes include c-MYC [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/86\">",
"     86",
"    </a>",
"    ] and the TCL1 oncogene in the case of immunoblastic lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/96\">",
"     96",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that serum levels of soluble CD23, a B cell stimulatory factor, are markedly elevated in AIDS patients with lymphoma, as compared with those without lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/97\">",
"     97",
"    </a>",
"    ]. This finding suggests that chronic B cell stimulation is a significant factor in the induction of lymphoma in this setting, and raises the possibility that soluble CD23 may be an early marker for the development of NHL.",
"   </p>",
"   <p>",
"    The frequency of EBV positivity varies by lymphoma subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, for example, only 30 to 40 percent of Burkitt lymphomas were EBV-positive compared with 79 percent of immunoblastic or large cell lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/85,101,102\">",
"       85,101,102",
"      </a>",
"      ]. In the former type of lymphoma, cellular immunity is relatively preserved when compared with AIDS-related lymphomas of the latter histologies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/50,87\">",
"       50,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      EBV is seen in the majority of primary effusion lymphoma cases [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/103-105\">",
"       103-105",
"      </a>",
"      ], but infection with human herpesvirus-8 (also called Kaposi's sarcoma-associated herpesvirus or KSHV) is thought to be of primary importance.",
"     </li>",
"     <li>",
"      EBV has been detected in 74 percent of AIDS-related plasmablastic lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/106,107\">",
"       106,107",
"      </a>",
"      ]. In one series, all cases were positive for Epstein Barr virus-encoded RNA (EBER) but lacked EBV late membrane proteins (LMP) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      EBV infection has been detected in virtually all patients with AIDS-related primary CNS lymphoma (PCNSL) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/42,43,109\">",
"       42,43,109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of AIDS-related PCNSL is strongly related to Epstein-Barr virus infection (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]. In one report, for example, EBV transcripts and expression of a viral protein were seen in all 21 cases of AIDS-related PCNSL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/43\">",
"     43",
"    </a>",
"    ]. EBV DNA sequences can also be detected in the cerebrospinal fluid (CSF) of these patients, which may assist in making the diagnosis. In one series of HIV-infected patients with focal brain lesions, EBV DNA sequences were detected in the CSF in 24 of 30 patients (80 percent) with PCNSL compared with none of 61 patients without PCNSL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small number of circulating B cells enter the central nervous system, and may do so in increased numbers as HIV infection advances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/111\">",
"     111",
"    </a>",
"    ]. EBV establishes latent, life-long infection in over 95 percent of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/89\">",
"     89",
"    </a>",
"    ]. During the course of HIV infection, EBV-specific T cells progressively lose the capacity to produce interferon-gamma in response to EBV peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/95\">",
"     95",
"    </a>",
"    ]. In addition, EBV-positive B lymphocytes occur more frequently in the CNS of HIV-infected individuals than in normal brains [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     HHV-8",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant cells of primary effusion lymphoma (PEL) are monoclonal B cells that contain genomic material from human herpesvirus-8 (HHV-8, also called Kaposi's sarcoma-associated herpesvirus or KSHV) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Details on the pathobiology of this NHL subtype are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link&amp;anchor=H3#H3\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence of HHV-8 infection has also been reported in plasmablastic lymphoma, with a prevalence ranging from 17 to 100 percent in several case series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/107,112,113\">",
"     107,112,113",
"    </a>",
"    ]. HHV-8+,",
"    <span class=\"nowrap\">",
"     CD138+/CD20-negative",
"    </span>",
"    lymphomas occurring outside of the oral cavity have also described as a solid-variant of PEL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multicentric Castleman's Disease, while not typically a clonal disorder, is an HIV-associate lymphoproliferative disease associated with low CD4 count and other HHV-8-positive malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. HHV-8 is present in almost all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H10#H10\">",
"     \"Castleman's disease\", section on 'Multicentric Castleman's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gene Dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS-related diffuse large B cell lymphoma (DLBCL) displays several genotypic differences compared with DLBCL of the immunocompetent host, although an explanation for the genetic peculiarities of AIDS-DLBCL remains obscure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/101\">",
"     101",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to DLBCL arising in immunocompetent hosts, BCL-2 activation is generally not seen in AIDS-DLBCL.",
"     </li>",
"     <li>",
"      Mutations resulting in deregulation of the BCL-6 proto-oncogene are seen in only 20 percent of AIDS-related DLBCL [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/101,118\">",
"       101,118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      c-MYC translocations occur in about 20 percent of AIDS-DLBCL; these occur less commonly in DLBCL in the HIV-seronegative population [",
"      <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further description of the molecular pathogenesis of DLBCL and BL in immunocompetent hosts is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link\">",
"     \"Pathobiology of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     BCL-6 expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations resulting in deregulation of the BCL-6 proto-oncogene are present in over 70 percent of AIDS-related lymphomas of all histologies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/119\">",
"     119",
"    </a>",
"    ], but only 20 percent of AIDS-related DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/101,118\">",
"     101,118",
"    </a>",
"    ]. These may result from translocations of promoters not intrinsic to the normal BCL-6 gene leading to increased BCL-6 expression, or to mutations in the 5' non-coding region of the BCL-6 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. In normal physiology, BCL-6 expression is restricted to germinal center cells, and is required for normal germinal center formation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Aberrant BCL-6 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In normal lymph node physiology, BCL-6 may prevent developing lymphocytes from undergoing apoptosis in response to the normal DNA breaks required for lymphocyte development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/76,122\">",
"     76,122",
"    </a>",
"    ]. AIDS-related lymphomas with BCL-6 activation without other genetic lesions (denoting germinal center etiology) tend to have a better prognosis compared with those with a post-germinal center (BCL-6 negative) origin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under normal circumstances, germinal center (GC) cells stop expressing the product of the BCL-6 gene and go on to express the CD-138 antigen (syndecan-1), marking their differentiation into plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/126\">",
"     126",
"    </a>",
"    ]. Malignant transformation of GC cells that express BCL-6 and have not yet expressed the CD-138 antigen",
"    <span class=\"nowrap\">",
"     (BCL-6+/syndecan-1-)",
"    </span>",
"    develop along the histologic pathway of Burkitt-like or large non-cleaved cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/119,127\">",
"     119,127",
"    </a>",
"    ]. Upon cessation of expression of the product of the BCL-6 gene and expression of the CD-138 (syndecan-1) antigen, cells that undergo malignant transformation may express the LMP-1 antigen characteristic of infection by EBV",
"    <span class=\"nowrap\">",
"     (BCL-6-/syndecan-1+/LMP-1+),",
"    </span>",
"    producing lymphomas of immunoblastic-plasmacytoid histology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/127-129\">",
"     127-129",
"    </a>",
"    ]. If they do not express LMP-1",
"    <span class=\"nowrap\">",
"     (BCL-6-/syndecan-1+/LMP-1-),",
"    </span>",
"    they tend to develop into primary effusion lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/128,130\">",
"     128,130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     c-MYC overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular pathogenesis of AIDS-related Burkitt lymphoma (BL) in Western countries involves c-MYC activation and Epstein-Barr virus (EBV) infection in 100 percent and 30 percent of the cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/75,131\">",
"     75,131",
"    </a>",
"    ]. The location of c-MYC breakpoints in AIDS-BL, as well as the frequency of EBV infection, indicates that the molecular pathogenesis of AIDS-BL in Western countries closely mimics that of sporadic BL of the immunocompetent host rather than endemic BL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/75\">",
"     75",
"    </a>",
"    ]. However, AIDS-BL occurring in Africa is strongly associated with EBV infection, suggesting a greater relation to endemic BL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link\">",
"     \"Pathobiology of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The breakpoints within the c-MYC gene differ between endemic and HIV-related Burkitt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/35\">",
"     35",
"    </a>",
"    ]. Virtually all of the cells of AIDS-BL contain a reciprocal chromosomal translocation that places the c-MYC gene adjacent to the immunoglobulin loci, resulting in the loss of regulation and constitutive expression of this proto-oncogene that encodes for a nuclear phospho-protein that permits the aberrant lymphocytes to be in a perpetually proliferative state [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/35,101,131\">",
"     35,101,131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    c-MYC translocations occur in about 20 percent of AIDS-DLBCL; these occur less commonly in DLBCL in the HIV-seronegative population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     p53 Mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 60 percent of cases of AIDS-related Burkitt-like lymphomas harbor mutations in the p53 tumor suppressor gene that result in deregulation of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/132-135\">",
"     132-135",
"    </a>",
"    ]. One pathology review of 66 cases of DLBCL showed that of the 11 of 13 cases with",
"    <span class=\"nowrap\">",
"     plasmablastic/plasmacytoid",
"    </span>",
"    features had a monoallelic p53 deletion by fluorescence in situ hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Aberrant Somatic Hypermutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aberrant somatic hypermutation activity described in DLBCL of immunocompetent hosts has also been reported in a large proportion of AIDS-NHLs, including Burkitt lymphoma, primary effusion lymphoma and primary central nervous system lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/36/20042/abstract/137,138\">",
"     137,138",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are seropositive for HIV have a substantially increased risk of cancer. Twenty-five to 40 percent of HIV-positive patients will develop a malignancy, with approximately 10 percent developing a non-Hodgkin lymphoma (NHL). Although variable according to histologic subtype, the overall incidence of NHL has declined with the widespread use of highly active antiretroviral therapy (HAART). Nevertheless, the incidence of NHL in HIV seropositive patients remains above that of the non-HIV-infected population. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'General issues'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Effect of HAART'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    AIDS-related NHL can be divided into three general categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic NHL (&gt;80 percent)",
"     </li>",
"     <li>",
"      Primary central nervous system (CNS) lymphoma (15 percent)",
"     </li>",
"     <li>",
"      Primary effusion (or body cavity) lymphoma (&lt;5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common systemic NHL subtypes seen in HIV-positive persons are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Burkitt lymphoma (approximately 25 percent)",
"     </li>",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL, approximately 75 percent)",
"     </li>",
"     <li>",
"      Plasmablastic lymphoma (less than 1 percent)",
"     </li>",
"     <li>",
"      T cell lymphoma (1 to 3 percent)",
"     </li>",
"     <li>",
"      Indolent B cell lymphoma (&lt;10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While many NHL subtypes are also seen in patients without immunocompromise, primary effusion lymphoma and plasmablastic lymphoma occur predominantly in immunocompromised patients, particularly those infected with HIV. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Specific NHL subtypes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk factors for AIDS-related lymphoma include both HIV-specific risk factors, such as a low CD4 count and high HIV viral load, and more general risk factors known to increase the risk of NHL in patients without HIV. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Past history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of NHL in the setting of HIV infection is poorly understood, but immune deregulation leading to loss of control of viruses, such as Epstein Barr virus is thought to play an important role. AIDS-related NHLs are most commonly derived from B cells. There is an unregulated expansion of these B cells that are arrested in development and unable to undergo terminal differentiation. Genetic alterations may be involved, not only in the pathogenesis of AIDS-related lymphomas, but also in determining the histology of the resulting clonal proliferation(s). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pathobiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1106472\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Caroline M Behler, MD, MS, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/1\">",
"      Levine AM. AIDS-related malignancies. Curr Opin Oncol 1994; 6:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/2\">",
"      Conant MA. Management of human immunodeficiency virus-associated malignancies. Recent Results Cancer Res 1995; 139:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/3\">",
"      Rabkin CS. Epidemiology of AIDS-related malignancies. Curr Opin Oncol 1994; 6:492.",
"     </a>",
"    </li>",
"    <li>",
"     Levine AM, Pieters AS. Non-AIDS defining cancer. In: of the First National AIDS Malignancy Conference, National Cancer Institute, Bethesda, MD 1997. p.18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/5\">",
"      Akanmu AS. AIDS-associated malignancies. Afr J Med Med Sci 2006; 35 Suppl:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/6\">",
"      G&eacute;rard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/7\">",
"      Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/8\">",
"      Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011; 305:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/9\">",
"      White DA. Pulmonary complications of HIV-associated malignancies. Clin Chest Med 1996; 17:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/10\">",
"      Tossing G. Immunodeficiency and its relation to lymphoid and other malignancies. Ann Hematol 1996; 73:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/11\">",
"      Barchielli A, Buiatti E, Galanti C, Lazzeri V. Linkage between AIDS surveillance system and population-based cancer registry data in Italy: a pilot study in Florence, 1985-90. Tumori 1995; 81:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/12\">",
"      Johnson CC, Wilcosky T, Kvale P, et al. Cancer incidence among an HIV-infected cohort. Pulmonary Complications of HIV Infection Study Group. Am J Epidemiol 1997; 146:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/13\">",
"      Biggar RJ, Rabkin CS. The epidemiology of AIDS--related neoplasms. Hematol Oncol Clin North Am 1996; 10:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/14\">",
"      Koblin BA, Hessol NA, Zauber AG, et al. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol 1996; 144:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/15\">",
"      Armenian HK, Hoover DR, Rubb S, et al. Risk factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 1996; 143:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/16\">",
"      Tirelli U, Franceschi S, Carbone A. Malignant tumours in patients with HIV infection. BMJ 1994; 308:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/17\">",
"      Gabutti G, Vercelli M, De Rosa MG, et al. AIDS related neoplasms in Genoa, Italy. Eur J Epidemiol 1995; 11:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/18\">",
"      Biggar RJ, Rosenberg PS, Cot&eacute; T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996; 68:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/19\">",
"      Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/20\">",
"      Hartge P, Devesa SS, Fraumeni JF Jr. Hodgkin's and non-Hodgkin's lymphomas. Cancer Surv 1994; 19-20:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/21\">",
"      Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/22\">",
"      Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/23\">",
"      Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/24\">",
"      Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/25\">",
"      Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/26\">",
"      Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/27\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/28\">",
"      Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Pleural and peritoneal lymphoma among people with AIDS in the United States. J Acquir Immune Defic Syndr 2002; 29:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/29\">",
"      Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21:3948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/30\">",
"      Mantina H, Wiggill TM, Carmona S, et al. Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr 2010; 53:656.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/32\">",
"      Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010; 116:5600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/33\">",
"      Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000; 96:4084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/34\">",
"      Said JW. Human immunodeficiency virus-related lymphoid proliferations. Semin Diagn Pathol 1997; 14:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/35\">",
"      Ferry JA. Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006; 11:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/36\">",
"      Arzoo KK, Bu X, Espina BM, et al. T-cell lymphoma in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/37\">",
"      Levine AM, Sadeghi S, Espina B, et al. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer 2002; 94:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/38\">",
"      Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003; 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/39\">",
"      Biggar RJ, Engels EA, Frisch M, et al. Risk of T-cell lymphomas in persons with AIDS. J Acquir Immune Defic Syndr 2001; 26:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/40\">",
"      Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol 2002; 33:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/41\">",
"      Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol 1996; 8:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/42\">",
"      Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/43\">",
"      MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/44\">",
"      Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/45\">",
"      Rabkin CS, Hilgartner MW, Hedberg KW, et al. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA 1992; 267:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/46\">",
"      Pluda JM, Yarchoan R, Jaffe ES, et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/47\">",
"      Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010; 54:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/48\">",
"      Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/49\">",
"      Guiguet M, Bou&eacute; F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/50\">",
"      Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993; 11:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/51\">",
"      Gabarre J, Raphael M, Lepage E, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med 2001; 111:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/52\">",
"      DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol 1998; 25:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/53\">",
"      Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am 1996; 10:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/54\">",
"      Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 2003; 4:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/55\">",
"      Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/56\">",
"      G&eacute;rard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/57\">",
"      Killebrew D, Shiramizu B. Pathogenesis of HIV-associated non-Hodgkin lymphoma. Curr HIV Res 2004; 2:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/58\">",
"      Petoumenos K, van Leuwen MT, Vajdic CM, et al. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Med 2013; 14:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/59\">",
"      Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/60\">",
"      Detels R, Mu&ntilde;oz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/61\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/62\">",
"      Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/63\">",
"      Polesel J, Franceschi S, Suligoi B, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/64\">",
"      Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/65\">",
"      Berretta M, Cinelli R, Martellotta F, et al. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003; 22:6646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/66\">",
"      Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/67\">",
"      Palmieri C, Treibel T, Large O, Bower M. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM 2006; 99:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/68\">",
"      Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/69\">",
"      Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/70\">",
"      Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 28:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/71\">",
"      Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59:3561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/72\">",
"      Rabkin CS, Yang Q, Goedert JJ, et al. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. Blood 1999; 93:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/73\">",
"      D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997; 27:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/74\">",
"      Wang SS, Slager SL, Brennan P, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 109:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/75\">",
"      Gormley RP, Madan R, Dulau AE, et al. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. Am J Clin Pathol 2005; 124:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/76\">",
"      Shearer GM. HIV-induced immunopathogenesis. Immunity 1998; 9:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/77\">",
"      Biancotto A, Grivel JC, Iglehart SJ, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109:4272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/78\">",
"      Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997; 3 Suppl 1:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/79\">",
"      Moses AV, Williams SE, Strussenberg JG, et al. HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas. Nat Med 1997; 3:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/80\">",
"      Chirivi RG, Taraboletti G, Bani MR, et al. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Blood 1999; 94:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/81\">",
"      Ballerini P, Gaidano G, Gong JZ, et al. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 1993; 81:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/82\">",
"      De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene 2003; 22:6214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/83\">",
"      Aoki Y, Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord 2003; 3:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/84\">",
"      Ometto L, Menin C, Masiero S, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997; 90:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/85\">",
"      Hamilton-Dutoit SJ, Pallesen G, Karkov J, et al. Identification of EBV-DNA in tumour cells of AIDS-related lymphomas by in-situ hybridisation. Lancet 1989; 1:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/86\">",
"      Pelicci PG, Knowles DM 2nd, Arlin ZA, et al. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med 1986; 164:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/87\">",
"      Kersten MJ, Klein MR, Holwerda AM, et al. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest 1997; 99:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/88\">",
"      Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 1986; 314:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/89\">",
"      Paludan C, M&uuml;nz C. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus. Curr Mol Med 2003; 3:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/90\">",
"      Piriou E, van Dort K, Nanlohy NM, et al. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005; 106:3166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/91\">",
"      Carbone A, Tirelli U, Gloghini A, et al. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993; 11:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/92\">",
"      Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993; 143:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/93\">",
"      Piriou ER, van Dort K, Nanlohy NM, et al. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol 2004; 172:6931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/94\">",
"      Van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002; 186:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/95\">",
"      van Baarle D, Hovenkamp E, Callan MF, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001; 98:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/96\">",
"      Teitell M, Damore MA, Sulur GG, et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci U S A 1999; 96:9809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/97\">",
"      Yawetz S, Cumberland WG, van der Meyden M, Mart&iacute;nez-Maza O. Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin's lymphoma. Blood 1995; 85:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/98\">",
"      Shiramizu B, McGrath MS. Molecular pathogenesis of AIDS-associated non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1991; 5:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/99\">",
"      Delecluse HJ, Raphael M, Magaud JP, et al. Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. Blood 1993; 82:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/100\">",
"      Kersten MJ, Van Gorp J, Pals ST, et al. Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. Leuk Lymphoma 1998; 30:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/101\">",
"      Gaidano G, Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv Cancer Res 1995; 67:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/102\">",
"      Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005; 130:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/103\">",
"      Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/104\">",
"      Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/105\">",
"      Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997; 90:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/106\">",
"      Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/107\">",
"      Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, et al. Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/108\">",
"      Dong HY, Scadden DT, de Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 2005; 29:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/109\">",
"      Guterman KS, Hair LS, Morgello S. Epstein-Barr virus and AIDS-related primary central nervous system lymphoma. Viral detection by immunohistochemistry, RNA in situ hybridization, and polymerase chain reaction. Clin Neuropathol 1996; 15:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/110\">",
"      Cingolani A, De Luca A, Larocca LM, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 1998; 90:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/111\">",
"      Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 2003; 126:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/112\">",
"      Cioc AM, Allen C, Kalmar JR, et al. Oral plasmablastic lymphomas in AIDS patients are associated with human herpesvirus 8. Am J Surg Pathol 2004; 28:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/113\">",
"      Deloose ST, Smit LA, Pals FT, et al. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. Leukemia 2005; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/114\">",
"      Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/115\">",
"      Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002; 99:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/116\">",
"      Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008; 140:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/117\">",
"      Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/118\">",
"      Gaidano G, Lo Coco F, Ye BH, et al. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. Blood 1994; 84:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/119\">",
"      Gaidano G, Capello D, Carbone A. The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. Semin Oncol 2000; 27:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/120\">",
"      Dalla-Favera R, Migliazza A, Chang CC, et al. Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immunol 1999; 246:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/121\">",
"      Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A 1995; 92:12520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/122\">",
"      Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/123\">",
"      Dent AL, Shaffer AL, Yu X, et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/124\">",
"      Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997; 16:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/125\">",
"      Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/126\">",
"      Gaidano G, Cerri M, Capello D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol 2002; 119:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/127\">",
"      Carbone A, Gaidano G, Gloghini A, et al. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am J Pathol 1997; 150:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/128\">",
"      Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998; 91:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/129\">",
"      Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998; 92:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/130\">",
"      Gaidano G, Gloghini A, Gattei V, et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood 1997; 90:4894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/131\">",
"      Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 1998; 16:3788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/132\">",
"      Bhatia K, Spangler G, Gaidano G, et al. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood 1994; 84:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/133\">",
"      Gu W, Bhatia K, Magrath IT, et al. Binding and suppression of the Myc transcriptional activation domain by p107. Science 1994; 264:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/134\">",
"      Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/135\">",
"      Duval A, Raphael M, Brennetot C, et al. The mutator pathway is a feature of immunodeficiency-related lymphomas. Proc Natl Acad Sci U S A 2004; 101:5002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/136\">",
"      Simonitsch-Klupp I, Hauser I, Ott G, et al. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004; 18:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/137\">",
"      Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 2003; 102:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/36/20042/abstract/138\">",
"      Capello D, Martini M, Gloghini A, et al. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica 2008; 93:1178.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4726 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20042=[""].join("\n");
var outline_f19_36_20042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Specific NHL subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CD4 count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HIV viral load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of HAART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      B cell abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Immune dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - EBV coinfection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - HHV-8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gene Dysregulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - BCL-6 expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - c-MYC overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - p53 Mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Aberrant Somatic Hypermutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1106472\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4726|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/56/2958\" title=\"figure 1\">",
"      NHL distribution by HAART use and CD4 count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4726|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/49/25371\" title=\"table 1\">",
"      HIV-associated lymphomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/26/42412\" title=\"table 2\">",
"      Classification of NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7321?source=related_link\">",
"      AIDS-related lymphomas: Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=related_link\">",
"      Pathobiology of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=related_link\">",
"      Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_36_20043="Prevention outdoor infestation";
var content_f19_36_20043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of outdoor fire ant infestation at health care facilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The first 25 to 50 feet around the outside of a building should be considered a critical zone and regularly surveyed for fire ant infestation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allow 18 to 20 inches of clear air space between the building and the mature height and width of ornamental plants.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If irrigation is used, make sure sprinkler heads are pointed away from the building and not positioned so as to wet the building, thus providing moisture for insect infestation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep the soil grade sloping away from the building to prevent accumulation of water against the foundation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If rain gutters are used, make sure that down spouts are clear and water runs freely away from the facility.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contract with a pest control service to routinely inspect and, if appropriate, apply insecticides to keep the perimeter of health care facilities free of fire ant infestation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goddard J, Jarratt J, deShazo RD. Recommendations for prevention and management of fire ant infestation of health care facilities. South Med J 2002; 95:627. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20043=[""].join("\n");
var outline_f19_36_20043=null;
var title_f19_36_20044="Causes neonatal acute kidney injury";
var content_f19_36_20044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acute kidney injury in newborns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prerenal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septicemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoalbuminemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal asphyxia/respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital heart disease/cardiac surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharmacologic agents*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Post-renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior urethral valves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral obstructive uropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurogenic bladder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrinsic renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute tubular necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticomedullary necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal venous/arterial thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pyelonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin/myoglobin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoimmune hemolytic disease with massive hemoglobinuira",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital renal anomalies (renal agenesis, cystic disease/dysplasia, polycystic kidney disease, congenital nephrotic syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections (eg, pyelonephritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrauterine infections (eg, candidiasis, toxoplasmosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic nephropathy due to pharmacologic agents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes agents, such as prostaglandin inhibitors (indomethacin), angiotensin-converting enzyme inhibitors (captopril), and vasodilators. Drugs, such as aminoglycosides, amphotericin, and radiocontrast agents cause prerenal as well as intrinsic renal failure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20044=[""].join("\n");
var outline_f19_36_20044=null;
var title_f19_36_20045="Cumulative incidence of AF in individuals with HF";
var content_f19_36_20045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Cumulative incidence of AF in individuals with HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 323px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In an analysis from the Framingham Heart Study of 708 patients with heart failure (HF) who were in sinus rhythm, 159 (22 percent) developed atrial fibrillation (AF) at an average of 4.2 years of follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107:2920.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20045=[""].join("\n");
var outline_f19_36_20045=null;
var title_f19_36_20046="Long term GH in TS";
var content_f19_36_20046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of GH in Turner syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 459px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-term growth hormone (GH) dose-response results in Turner syndrome. Individual heights at the start of the study (white circles) and after seven years of GH treatment (red circles). Reference curves for healthy Dutch girls (solid lines) (3rd, 10th, 50th, 90th, and 97th percentiles) and for untreated girls with TS (dotted lines) (North European references; 3rd, 50th, and 97th percentiles) are given.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 1999; 84:4607.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20046=[""].join("\n");
var outline_f19_36_20046=null;
var title_f19_36_20047="Mechanism organophos pralidox";
var content_f19_36_20047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Mechanism of action: Organophosphate and pralidoxime",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 435px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_36_20047=[""].join("\n");
var outline_f19_36_20047=null;
